Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders

array:25 ["pii" => "S2173580821000237" "issn" => "21735808" "doi" => "10.1016/j.nrleng.2018.12.021" "estado" => "S300" "fechaPublicacion" => "2022-04-01" "aid" => "1289" "copyright" => "Sociedad Española de Neurología" "copyrightAnyo" => "2019" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Neurologia. 2022;37:178-83" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "es" => array:20 [ "pii" => "S0213485319300337" "issn" => "02134853" "doi" => "10.1016/j.nrl.2018.12.013" "estado" => "S300" "fechaPublicacion" => "2022-04-01" "aid" => "1289" "copyright" => "Sociedad Española de Neurología" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Neurologia. 2022;37:178-83" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 889 "formatos" => array:3 [ "EPUB" => 54 "HTML" => 440 "PDF" => 395 ] ] "es" => array:12 [ "idiomaDefecto" => true "cabecera" => "ORIGINAL" "titulo" => "Experiencia con tocilizumab en pacientes con espectro de la neuromielitis óptica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "tieneResumen" => array:2 [ 0 => "es" 1 => "en" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "178" "paginaFinal" => "183" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders" ] ] "contieneResumen" => array:2 [ "es" => true "en" => true ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. Carreón Guarnizo, R. Hernández Clares, T. Castillo Triviño, V. Meca Lallana, V. Arocas Casañ, F. Iniesta Martínez, J. Olascoaga Urtaza, J.E. Meca Lallana" "autores" => array:8 [ 0 => array:2 [ "nombre" => "E." "apellidos" => "Carreón Guarnizo" ] 1 => array:2 [ "nombre" => "R." "apellidos" => "Hernández Clares" ] 2 => array:2 [ "nombre" => "T." "apellidos" => "Castillo Triviño" ] 3 => array:2 [ "nombre" => "V." "apellidos" => "Meca Lallana" ] 4 => array:2 [ "nombre" => "V." "apellidos" => "Arocas Casañ" ] 5 => array:2 [ "nombre" => "F." "apellidos" => "Iniesta Martínez" ] 6 => array:2 [ "nombre" => "J." "apellidos" => "Olascoaga Urtaza" ] 7 => array:2 [ "nombre" => "J.E." "apellidos" => "Meca Lallana" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2173580821000237" "doi" => "10.1016/j.nrleng.2018.12.021" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580821000237?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485319300337?idApp=UINPBA00004N" "url" => "/02134853/0000003700000003/v1_202203290758/S0213485319300337/v1_202203290758/es/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S2173580821000225" "issn" => "21735808" "doi" => "10.1016/j.nrleng.2018.12.020" "estado" => "S300" "fechaPublicacion" => "2022-04-01" "aid" => "1288" "copyright" => "Sociedad Española de Neurología" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Neurologia. 2022;37:184-91" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "Ischaemic stroke as a complication of cardiac catheterisation. Clinical and radiological characteristics, progression, and therapeutic implications" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "184" "paginaFinal" => "191" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Ictus isquémico como complicación del cateterismo cardíaco. Características clínicas, radiológicas y evolutivas e implicaciones terapéuticas" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1192 "Ancho" => 2083 "Tamanyo" => 172562 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Flow chart illustrating the patient selection process." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "L. Martín-Aguilar, M. Paré-Curell, L. Dorado, N. Pérez de la Ossa-Herrero, A. Ramos-Pachón, E. López-Cancio, E. Fernández-Nofrerias, O. Rodríguez-Leor, C. Castaño, S. Remollo, P. Puyalto, P. Cuadras, M. Millán, A. Dávalos, M. Hernández-Pérez" "autores" => array:15 [ 0 => array:2 [ "nombre" => "L." "apellidos" => "Martín-Aguilar" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Paré-Curell" ] 2 => array:2 [ "nombre" => "L." "apellidos" => "Dorado" ] 3 => array:2 [ "nombre" => "N." "apellidos" => "Pérez de la Ossa-Herrero" ] 4 => array:2 [ "nombre" => "A." "apellidos" => "Ramos-Pachón" ] 5 => array:2 [ "nombre" => "E." "apellidos" => "López-Cancio" ] 6 => array:2 [ "nombre" => "E." "apellidos" => "Fernández-Nofrerias" ] 7 => array:2 [ "nombre" => "O." "apellidos" => "Rodríguez-Leor" ] 8 => array:2 [ "nombre" => "C." "apellidos" => "Castaño" ] 9 => array:2 [ "nombre" => "S." "apellidos" => "Remollo" ] 10 => array:2 [ "nombre" => "P." "apellidos" => "Puyalto" ] 11 => array:2 [ "nombre" => "P." "apellidos" => "Cuadras" ] 12 => array:2 [ "nombre" => "M." "apellidos" => "Millán" ] 13 => array:2 [ "nombre" => "A." "apellidos" => "Dávalos" ] 14 => array:2 [ "nombre" => "M." "apellidos" => "Hernández-Pérez" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213485319300325" "doi" => "10.1016/j.nrl.2018.12.012" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485319300325?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580821000225?idApp=UINPBA00004N" "url" => "/21735808/0000003700000003/v1_202204220526/S2173580821000225/v1_202204220526/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S2173580821000444" "issn" => "21735808" "doi" => "10.1016/j.nrleng.2019.03.017" "estado" => "S300" "fechaPublicacion" => "2022-04-01" "aid" => "1295" "copyright" => "Sociedad Española de Neurología" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "Neurologia. 2022;37:171-7" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "Epilepsy in elderly patients: does age of onset make a difference?" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "171" "paginaFinal" => "177" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Epilepsia en el anciano: ¿la edad de inicio marca la diferencia?" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:8 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 983 "Ancho" => 2122 "Tamanyo" => 111896 ] ] "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Figure " "rol" => "short" ] ] "descripcion" => array:1 [ "en" => "Number of elderly patients in groups A (disease onset before 65 years of age) and B (onset at or after 65 years) in whom different antiepileptic drugs were tried and who continued treatment with these drugs (results are expressed as absolute numbers). Mean doses (mg/24 h) with standard deviations and ranges (mg/24 h) are also indicated. CBZ: carbamazepine; CLB: clobazam; ESL: eslicarbazepine; GBT: gabapentin; LCS: lacosamide; LEV: levetiracetam; LTG: lamotrigine; OXC: oxcarbazepine; PB: phenobarbital; PGB: pregabalin; PHT: phenytoin; PRM: primidone; RFN: rufinamide; TPM: topiramate; VPA: valproic acid; ZNS: zonisamide." ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Suller Marti, E. Bellosta Diago, P. Vinueza Buitron, A. Velázquez Benito, S. Santos Lasaosa, J.Á. Mauri Llerda" "autores" => array:6 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Suller Marti" ] 1 => array:2 [ "nombre" => "E." "apellidos" => "Bellosta Diago" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Vinueza Buitron" ] 3 => array:2 [ "nombre" => "A." "apellidos" => "Velázquez Benito" ] 4 => array:2 [ "nombre" => "S." "apellidos" => "Santos Lasaosa" ] 5 => array:2 [ "nombre" => "J.Á." "apellidos" => "Mauri Llerda" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0213485319300453" "doi" => "10.1016/j.nrl.2019.03.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485319300453?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580821000444?idApp=UINPBA00004N" "url" => "/21735808/0000003700000003/v1_202204220526/S2173580821000444/v1_202204220526/en/main.assets" ] "en" => array:19 [ "idiomaDefecto" => true "cabecera" => "Original article" "titulo" => "Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "178" "paginaFinal" => "183" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "E. Carreón Guarnizo, R. Hernández Clares, T. Castillo Triviño, V. Meca Lallana, V. Arocas Casañ, F. Iniesta Martínez, J. Olascoaga Urtaza, J.E. Meca Lallana" "autores" => array:8 [ 0 => array:4 [ "nombre" => "E." "apellidos" => "Carreón Guarnizo" "email" => array:1 [ 0 => "strcg_2@hotmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "R." "apellidos" => "Hernández Clares" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "T." "apellidos" => "Castillo Triviño" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "V." "apellidos" => "Meca Lallana" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "d" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "V." "apellidos" => "Arocas Casañ" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "e" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "F." "apellidos" => "Iniesta Martínez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 6 => array:3 [ "nombre" => "J." "apellidos" => "Olascoaga Urtaza" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] 7 => array:3 [ "nombre" => "J.E." "apellidos" => "Meca Lallana" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] ] "afiliaciones" => array:5 [ 0 => array:3 [ "entidad" => "CSUR Esclerosis Múltiple y Unidad de Neuroinmunología Clínica, Servicio de Neurología, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM, Universidad Católica San Antonio, Murcia, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Unidad de Esclerosis Múltiple, Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Unidad de Esclerosis Múltiple, Servicio de Neurología, Hospital Universitario de La Princesa, Madrid, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Servicio de Farmacia, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Experiencia con tocilizumab en pacientes con espectro de la neuromielitis óptica" ] ] "textoCompleto" => "IntroductionNeuromyelitis optica spectrum disorders (NMOSD) are inflammatory diseases of the central nervous system; the main pathogenic mechanism is mediated by the action of aquaporin-4 antibodies (AQP4-IgG), which target aquaporin-4 channels (AQP4), the most abundant water channels in the central nervous system. The clinical course includes recurrent outbreaks (only 5%-10% are monophasic) of optic neuritis or transverse myelitis, although today the disease is considered to affect not only the optic nerves and the spinal cord, as initially described, but also the brainstem and brain hemispheres. Outbreaks are usually severe and the risk of disabling sequelae is high.<a class="elsevierStyleCrossRef" href="#bib0005">1</a>Immunosuppressants are the main disease-modifying treatments (DMT) used; however, no randomised controlled clinical trial has provided a sufficient level of evidence to conclusively support the use of any specific drug. The low incidence of the disease, together with the availability of effective treatment options, probably further decreases the number of cases available to be included in placebo-controlled trials. In clinical practice, therapeutic management is supported by results from small series of patients receiving different immunosuppressants. Although optimal responses to such treatments as azathioprine, mycophenolate mofetil, methotrexate, and mitoxantrone have been reported, the best outcomes were obtained with rituximab (RTX), a monoclonal antibody targeting the CD20 antigen of B cells, which has obtained response rates between 50% and 93%.<a class="elsevierStyleCrossRefs" href="#bib0010">2–8</a> The meta-analysis by Damto et al.,<a class="elsevierStyleCrossRef" href="#bib0045">9</a> which included 46 studies (n=438) of patients with NMOSD and treated with RTX, showed that RTX is an effective treatment for reducing relapses; however, due to the lack of controlled studies with results on safety, it should be used with caution as a first option. In spite of these results, between 7% and 47% of patients treated with RTX, according to different series, may present relapses, even with complete depletion of B cells.<a class="elsevierStyleCrossRefs" href="#bib0010">2–8</a>Different studies on the pathogenesis of NMOSD have reported significantly higher levels of proinflammatory interleukin 6 (IL-6) in serum and cerebrospinal fluid than in other autoimmune neurological diseases,<a class="elsevierStyleCrossRefs" href="#bib0050">10,11</a> which may mean that IL-6 has a relevant pathogenic role in these disorders. IL-6 would prolong the survival of certain B cell subclasses and the secretion of anti-AQP4 antibodies.<a class="elsevierStyleCrossRefs" href="#bib0060">12–14</a>Tocilizumab is a recombinant humanised monoclonal IgG1 antibody targeting the human IL-6 receptor. It is indicated as treatment for rheumatoid arthritis, and is dosed at 8mg/kg body weight, administered intravenously every 4 weeks. Tocilizumab has been shown to be effective in other autoimmune diseases, such as systemic lupus erythematosus.<a class="elsevierStyleCrossRef" href="#bib0075">15</a>Some studies using tocilizumab to treat NMOSD have shown decreased intrathecal levels of IL-6 in the cerebrospinal fluid, which are correlated with decreased disease activity, both clinically and in imaging studies.<a class="elsevierStyleCrossRef" href="#bib0080">16</a> Tocilizumab may be beneficial for treatment of some of the most frequent symptoms, such as fatigue and neuropathic pain.<a class="elsevierStyleCrossRef" href="#bib0070">14</a>Material and methodsThe aim of the study is to assess the effectiveness and safety of treatment with tocilizumab in patients with NMOSD who have not previously responded to other DMTs.This is an observational study including a retrospective analysis of a series of patients diagnosed with NMOSD at 3 reference hospitals for inflammatory and demyelinating diseases of the central nervous system. Inclusion criteria were: diagnosis of NMOSD according to the criteria proposed by Wingerchuck et al.<a class="elsevierStyleCrossRef" href="#bib0085">17</a> in 2015, previous ineffectiveness of one or several DMTs, and having used tocilizumab dosed at 8mg/kg body weight every 4 weeks after suspension of the last DMT due to lack of therapeutic response.Lack of response to a previous DMT was defined as the presence of a clinical relapse (optic neuropathy, myelitis, or brainstem syndrome) during exposure to the drug.We retrospectively gathered demographic data and information on disease progression from diagnosis of NMOSD to the time of drafting this study; therefore, tocilizumab exposure time is different in each patient. After being diagnosed, patients were periodically assessed by a neurologist specialising in demyelinating diseases.The primary outcome variable was the annualised relapse rate (ARR), determined by dividing the total number of relapses by a period of time in years, and calculated before and after each treatment. Secondary variables were the degree of disability, radiological progression in magnetic resonance imaging (MRI) studies, and the degree of tolerance and safety.To quantify the degree of disability we used the Expanded Disability Status Scale (EDSS), which is frequently used in multiple sclerosis. We collected all the data on brain and spinal MRI available during clinical follow-up, analysing gadolinium-enhanced T2-weighted, FLAIR, and T1-weighted sequences. We also analysed all the laboratory and clinical results related to safety from tocilizumab treatment onset.Differences between quantitative variables were measured with the paired samples t test.Patients signed informed consent forms and the drug was administered after its approval by the corresponding regulatory body as an off-label treatment.ResultsDemographic and baseline clinical characteristicsOf all the patients with NMOSD analysed, we identified 5 who met the inclusion criteria. Three patients (60%) were women. Mean age (SD) at diagnosis was 50 (5.3) years, and all patients had presented at least one episode of optic neuritis and one episode of longitudinally extensive transverse myelitis. No patient presented comorbid autoimmune diseases. Two patients presented AQP4-IgG in serum and none presented MOG-IgG. The transfected cell technique was used to quantify AQP4-IgG antibodies.As is required for other conditions treated with tocilizumab, latent tuberculosis and active infections were ruled out before treatment onset. No specific washout period was established (the minimum time elapsed was 6 months), but titres of total leukocytes, lymphocytes, neutrophils, and platelets had to be within the normal range before treatment administration.All patients had received RTX as a DMT at some point during progression (dosed at 375mg/m2 weekly for 4 weeks and a minimum of 1g after one year). Two had also been treated with cyclophosphamide and one with azathioprine. One patient had been previously diagnosed with multiple sclerosis and received sequential treatment with interferon beta and natalizumab before diagnosis of NMOSD.Despite the DMTs administered, patients presented a mean ARR (SD) of 1.8 (1.3) in the year prior to tocilizumab treatment onset and a mean EDSS score of 5.3 (2). At baseline (before starting on tocilizumab), 4 of the 5 patients (80%) presented considerable disease activity in terms of number and severity of relapses (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<elsevierMultimedia ident="tbl0005"></elsevierMultimedia>Effectiveness and safety of tocilizumabMean duration (SD) of treatment with tocilizumab was 2.3 (1) years. After tocilizumab was started, a drastic reduction was observed in the number of relapses; in fact, 4 (80%) patients did not experience relapses during follow-up. The only relapse observed, at 3 months after starting tocilizumab (patient 5, <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>) consisted of cervical myelitis with sensory involvement of the lower limbs, which completely resolved after a megadose of steroids. Although follow-up periods for treatment with tocilizumab were variable, all patients completed a minimum of one year (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>). During the first year of treatment, ARRs decreased by 88.9% with regard to the previous year (1.8 [1.3] vs 0.2 [0.4]; P<.05), and no significant variations were observed in the degree of disability as measured with the EDSS (5.3 [2] vs 5.2 [1.9]; P>.05).We analysed follow-up MRI scans performed the year after starting tocilizumab (mean time after treatment onset: 8.6 [3.1] months) and compared the results with the last available MRI from the year prior. No changes were observed between brain MRI studies. No patient presented new lesions on spinal cord T2-weighted sequences. The 2 patients with gadolinium-enhancing (Gd+) active spinal cord lesions presented reductions greater than 75% in the Gd+ area (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).The most relevant adverse events were one case of asymptomatic mild neutropaenia of 6 months’ duration (with subsequent spontaneous resolution) and one case of chronic urinary tract infection (already observed with previous DMT) in another patient.AQP4-IgG and IL-6 levels were not quantified during follow-up.DiscussionConsidering that NMOSD relapses are frequently disabling and present a high risk of sequelae, starting immunosuppressive DMT is essential for preventing recurrence. Currently, due to the lack of randomised clinical trials on the treatment of NMOSD, the available evidence is insufficient to recommend a specific immunosuppressive treatment; therefore, clinical experience takes on special relevance.The patient series reported to date have shown the effectiveness of tocilizumab in reducing the rate of relapses, without relevant adverse effects; however, these studies generally present isolated cases and small series of patients showing resistance to other treatments.<a class="elsevierStyleCrossRefs" href="#bib0070">14,16,18–20</a>One of the largest series, including 7 patients,<a class="elsevierStyleCrossRef" href="#bib0070">14</a> showed that treatment with tocilizumab in NMOSD reduces the ARR and improves EDSS score (level of evidence IV). Although the majority of patients receiving tocilizumab presented aggressive disease refractory to treatment with anti-CD20 antibodies, we suggest that the drug should be considered at earlier stages of NMOSD to improve patients’ quality of life. The series reported by Ringelstein et al.,<a class="elsevierStyleCrossRef" href="#bib0105">21</a> including 8 patients, showed the effectiveness and safety of tocilizumab, especially in patients presenting inadequate response to RTX. Both series<a class="elsevierStyleCrossRefs" href="#bib0070">14,21</a> showed improvements in radiological activity (Gd+), in addition to decreases in EDSS scores and antibody titres (AQP4-IgG) during treatment. Both studies reported a decrease in relapse frequency and intensity (mild-moderate), with patients presenting resolution without sequelae. Neither reported severe adverse events.Our results are similar to those reported in other series in terms of the decrease in ARRs, the absence of progression of disability, the absence of new MRI lesions, and the radiological improvement in patients with Gd+ lesions.Several studies have suggested that the administration of treatments indicated for multiple sclerosis (such as natalizumab) in patients with NMOSD does not provide any benefit for any clinical or radiological variable, and may even lead to poorer results in these parameters; therefore, their use is not recommended.<a class="elsevierStyleCrossRefs" href="#bib0100">20,22,23</a> In our series, one patient had been treated sequentially with interferon beta and natalizumab before diagnosis of NMOSD, and during that period he presented numerous episodes of optic neuropathy, resulting in severely impaired residual visual acuity (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>, patient 3).Patients treated with tocilizumab for rheumatoid arthritis have been reported to present a higher risk of infection, mainly urinary tract infections and reactivation of latent tuberculosis.<a class="elsevierStyleCrossRef" href="#bib0120">24</a> However, a low percentage of severe infections is reported in these patients at 5 years of treatment, which shows that tocilizumab has a good long-term safety profile.<a class="elsevierStyleCrossRef" href="#bib0125">25</a> The patients included in our series presented good tolerance to tocilizumab, and presented few adverse effects of any kind. We can mention one case of transient neutropaenia that did not lead to any secondary opportunistic infection.Our results, like those of previous studies, are characterised by good response to tocilizumab in aggressive, refractory NMOSD, which raises the question of the drug's potential effectiveness as a first-line DMT. At the time of writing, we are aware of an ongoing phase 3 clinical trial with the molecule SA237, an anti–IL-6 receptor monoclonal antibody.The main limitations of our study are its observational, retrospective design and the possible influence of regression toward the mean in the improvement in ARRs, although the good radiological findings lead us to suspect a limited influence.ConclusionsIn our experience, tocilizumab (8mg/kg body weight, administered intravenously every 4 weeks) seems to be a safe and effective treatment in patients with active NMOSD and not responding to other immunosuppressants, mainly RTX. Further controlled studies with larger patient samples and longer follow-up periods are needed to assess the effectiveness of tocilizumab in NMOSD.Conflicts of interestThe authors have no conflicts of interest to declare." "textoCompletoSecciones" => array:1 [ "secciones" => array:11 [ 0 => array:3 [ "identificador" => "xres1694983" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Method" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1501403" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1694984" "titulo" => "Resumen" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Método" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1501402" "titulo" => "Palabras clave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:2 [ "identificador" => "sec0010" "titulo" => "Material and methods" ] 6 => array:3 [ "identificador" => "sec0015" "titulo" => "Results" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0020" "titulo" => "Demographic and baseline clinical characteristics" ] 1 => array:2 [ "identificador" => "sec0025" "titulo" => "Effectiveness and safety of tocilizumab" ] ] ] 7 => array:2 [ "identificador" => "sec0030" "titulo" => "Discussion" ] 8 => array:2 [ "identificador" => "sec0035" "titulo" => "Conclusions" ] 9 => array:2 [ "identificador" => "sec0040" "titulo" => "Conflicts of interest" ] 10 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2018-07-02" "fechaAceptado" => "2018-12-22" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1501403" "palabras" => array:4 [ 0 => "Neuromyelitis optica" 1 => "Neuromyelitis optica spectrum disorders" 2 => "Tocilizumab" 3 => "Treatment" ] ] ] "es" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palabras clave" "identificador" => "xpalclavsec1501402" "palabras" => array:4 [ 0 => "Neuromielitis óptica" 1 => "Espectro de la neuromielitis óptica" 2 => "Tocilizumab" 3 => "Tratamiento" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "IntroductionNeuromyelitis optica spectrum disorders (NMOSD) are immune-mediated inflammatory disorders of the central nervous system involving astrocytes, B lymphocytes, anti-aquaporin 4, and such inflammatory mediators as interleukin-6. Several immunosuppressants are used in their treatment. Tocilizumab, an interleukin-6 receptor antagonist, may be a treatment option. MethodWe performed an observational, retrospective study analysing parameters of effectiveness (annualised relapse rate, disability, and radiological progression) and safety of tocilizumab in patients with NMOSD in whom previous immunosuppressant treatment had failed. We aimed to evaluate the effectiveness and safety of tocilizumab in clinical practice in patients with NMOSD not responding to other immunosuppressants. ResultsFive patients with NMOSD were analysed. Sixty percent of patients were women; mean age at diagnosis was 50±5.3 years and mean progression time was 4.5±3.6 years. Previously administered immunosuppressants were rituximab (in all 5), cyclophosphamide (2), and azathioprine (1). Mean time of exposure to tocilizumab was 2.3±1 years. Mean annualised relapse rate was 1.8±1.3 in the year prior to the introduction of tocilizumab and 0.2±0.4 the year after (P<.05), representing a reduction of 88.9%. ConclusionsIn our experience, tocilizumab is safe and effective in patients with NMOSD showing no response to other immunosuppressants." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Introduction" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Method" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "es" => array:3 [ "titulo" => "Resumen" "resumen" => "IntroducciónEl espectro de la neuromielitis óptica (ENMO) es una enfermedad inflamatoria del sistema nervioso central con patogenia inmunomediada que implica a astrocitos, linfocitos B, anticuerpos antiacuaporina 4 y mediadores inflamatorios como la interleucina 6. En su tratamiento se utilizan distintos inmunosupresores. Tocilizumab, un antagonista del receptor de interleucina 6, podría ser una opción de tratamiento. MétodoEstudio observacional y retrospectivo en el que se analizan parámetros de efectividad: tasa anualizada de recaídas, discapacidad y evolución radiológica, y seguridad de tocilizumab en pacientes con ENMO (Wingerchuk 2015) y fracaso de inmunosupresores previos. El objetivo es evaluar la efectividad y seguridad de tocilizumab en la práctica clínica en pacientes con diagnóstico de ENMO sin respuesta terapéutica a otros inmunosupresores. ResultadosSe analizan 5 pacientes (60% mujeres) con ENMO. Características basales (media±DE): edad al diagnóstico 50±5,3 años; tiempo de evolución desde el diagnóstico 4,5±3,6 años; inmunosupresores previos rituximab (5), ciclofosfamida (2) y azatioprina (1); tiempo de exposición a tocilizumab 2,3±1 años; tasa anual de recaídas un año pretocilizumab vs. un año postocilizumab 1,8±1,3 vs. 0,2±0,4 (p <0,05). Reducción de la tasa anual de recaídas al año de postocilizumab: 88,9%. ConclusionesEn nuestra experiencia, tocilizumab es seguro y efectivo en pacientes con ENMO sin respuesta a otros inmunosupresores." "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Introducción" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Método" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusiones" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "Please cite this article as: Carreón Guarnizo E, Hernández Clares R, Castillo Triviño T, Meca Lallana V, Arocas Casañ V, Iniesta Martínez F, et al. Experiencia con tocilizumab en pacientes con espectro de la neuromielitis óptica. Neurología. 2022;37:178–183." ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at0005" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "AQP4-IgG: aquaporin-4 antibodies; ARR: annualised relapse rate; AZA: azathriopine; CP: cyclophosphamide; DMT: disease-modifying treatment; EDSS: Expanded Disability Status Scale; Gd+: gadolinium-enhancing lesion; Gd−: lesion without gadolinium enhancement; ITP: immune thrombocytopaenia; MRI: magnetic resonance imaging; RTX: rituximab; UTI: urinary tract infection." "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 1 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 2 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 3 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 4 \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 5 \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="6" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Baseline characteristics</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Sex \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Man \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Man \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age at onset (years) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">39 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">51 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age at diagnosis (years) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">47 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">42 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">54 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">53 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AQP4-IgG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Positive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Positive \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MOG-IgG \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Negative \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Myelitis (n) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Optic neuritis (n) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="6" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="6" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Previous DMT for NMO</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Years of progression until first treatment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">EDSS before first treatment \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Treatments (years/relapses) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RTX (2/1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RTX (1.5/4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RTX (0.5/1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RTX (0.23/1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">AZA (3 months/2) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CP (1.7/1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CP (0.53/2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RTX (2 weeks/1) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Last DMT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RTX \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RTX \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">CP \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">RTX \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Mean ARR in the last year \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adverse events (DMT) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">ITP (RTX) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Haemorrhagic cystitis (CP) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">UTI (RTX, CP) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Pancytopaenia (AZA) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Serum sickness (RTX) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">EDSS at end of the last DMT \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MRI in the last year \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No new lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New spinal Gd− lesion \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New spinal Gd+ lesion \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New spinal GD– lesion \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">New spinal GD+ lesion \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="6" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " colspan="6" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Treatment with tocilizumab</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age at onset (years) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">51 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">56 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">45 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">55 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">55 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Disease progression time at onset (years) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Time taking tocilizumab (years) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.4 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Relapses after tocilizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (third month) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">EDSS at 1 year \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">EDSS in the last follow-up visit \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.5 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7.5 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adverse effects \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Neutropaenia \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">UTI \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">None \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MRI after tocilizumab (months) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">MRI results after tocilizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No new lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No new lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">> 75% reduction of the Gd+ area \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">No new lesions \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">< 75% reduction of the Gd+ area \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2881474.png" ] ] ] ] "descripcion" => array:1 [ "en" => "Patients’ baseline clinical characteristics and response to tocilizumab." ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:25 [ 0 => array:3 [ "identificador" => "bib0005" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Ghezzi" 1 => "R. Bergamaschi" 2 => "V. Martinelli" 3 => "M. Trojano" 4 => "M.R. Tola" 5 => "E. Merelli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00415-004-0271-0" "Revista" => array:6 [ "tituloSerie" => "J Neurol" "fecha" => "2004" "volumen" => "251" "paginaInicial" => "47" "paginaFinal" => "52" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14999489" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0010" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Jacob" 1 => "B.G. Weinshenker" 2 => "I. Violich" 3 => "N. McLinskey" 4 => "L. Krupp" 5 => "R.J. Fox" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archneur.65.11.noc80069" "Revista" => array:6 [ "tituloSerie" => "Arch Neurol" "fecha" => "2008" "volumen" => "65" "paginaInicial" => "1443" "paginaFinal" => "1448" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18779415" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0015" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S.H. Kim" 1 => "W. Kim" 2 => "X.F. Li" 3 => "I.J. Jung" 4 => "H.J. Kim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archneurol.2011.154" "Revista" => array:6 [ "tituloSerie" => "Arch Neurol" "fecha" => "2011" "volumen" => "68" "paginaInicial" => "1412" "paginaFinal" => "1420" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21747007" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0020" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "H.L. Pellkofer" 1 => "M. Krumbholz" 2 => "A. Berthele" 3 => "B. Hemmer" 4 => "L.A. Gerdes" 5 => "J. Havla" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1212/WNL.0b013e3182152881" "Revista" => array:6 [ "tituloSerie" => "Neurology" "fecha" => "2011" "volumen" => "76" "paginaInicial" => "1310" "paginaFinal" => "1315" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21482945" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0025" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of rituximab in refractory neuromyelitis optica" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Collongues" 1 => "D. Brassat" 2 => "E. Maillart" 3 => "P. Labauge" 4 => "J.C. Ouallet" 5 => "C. Carra-Dalliere" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1352458515602337" "Revista" => array:6 [ "tituloSerie" => "Mult Scler" "fecha" => "2016" "volumen" => "22" "paginaInicial" => "955" "paginaFinal" => "959" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26362900" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0030" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "S.U. Kim" 1 => "S.Y. Huh" 2 => "S.J. Lee" 3 => "A. Joung" 4 => "H.J.A. Kim" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamaneurol.2013.3071" "Revista" => array:7 [ "tituloSerie" => "JAMA Neurol" "fecha" => "2013" "volumen" => "70" "paginaInicial" => "1110" "paginaFinal" => "11175" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23897062" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0015028217304314" "estado" => "S300" "issn" => "00150282" ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0035" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Radaelli" 1 => "L. Moiola" 2 => "F. Sangalli" 3 => "F. Esposito" 4 => "V. Barcella" 5 => "L. Ferrè" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1352458515594042" "Revista" => array:6 [ "tituloSerie" => "Mult Scler" "fecha" => "2016" "volumen" => "22" "paginaInicial" => "511" "paginaFinal" => "519" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26199350" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0040" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Rituximab in the treatment of neuromyelitis optica: a multicentre Italian observational study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "P. Annovazzi" 1 => "M. Capobianco" 2 => "L. Moiola" 3 => "F. Patti" 4 => "J. Frau" 5 => "A. Uccelli" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00415-016-8188-y" "Revista" => array:6 [ "tituloSerie" => "J Neurol" "fecha" => "2016" "volumen" => "263" "paginaInicial" => "1727" "paginaFinal" => "1735" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27286847" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0045" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders. A systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "V. Damato" 1 => "A. Evoli" 2 => "R. Iorio" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamaneurol.2016.1637" "Revista" => array:6 [ "tituloSerie" => "JAMA Neurol" "fecha" => "2016" "volumen" => "73" "paginaInicial" => "1342" "paginaFinal" => "1348" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27668357" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0050" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Markedly increased CSF interlecukin-6 levels in NMO, but not in multiple sclerosis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Uzawa" 1 => "M. Mori" 2 => "M. Ito" 3 => "T. Uchida" 4 => "S. Hayakawa" 5 => "S. Masuda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00415-009-5274-4" "Revista" => array:6 [ "tituloSerie" => "J Neurol" "fecha" => "2009" "volumen" => "256" "paginaInicial" => "2082" "paginaFinal" => "2084" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19655191" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0055" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Uzawa" 1 => "M. Mori" 2 => "K. Arai" 3 => "Y. Sato" 4 => "S. Hayakawa" 5 => "S. Masuda" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1352458510379247" "Revista" => array:7 [ "tituloSerie" => "Mult Scler" "fecha" => "2010" "volumen" => "16" "paginaInicial" => "1443" "paginaFinal" => "1452" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20739337" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0010782408003776" "estado" => "S300" "issn" => "00107824" ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0060" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interleukin 6 signaling promotes antiaquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "N. Chihara" 1 => "T. Aranami" 2 => "W. Sato" 3 => "Y. Miyazaki" 4 => "S. Miyake" 5 => "T. Okamoto" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1073/pnas.1017385108" "Revista" => array:6 [ "tituloSerie" => "Proc Natl Acad Sci U S A" "fecha" => "2011" "volumen" => "108" "paginaInicial" => "3701" "paginaFinal" => "3706" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21321193" "web" => "Medline" ] ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0065" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "Içöz S1" 1 => "E. Tüzün" 2 => "M. Kürtüncü" 3 => "H. Durmuş" 4 => "M. Mutlu" 5 => "M. Eraksoy" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.3109/00207450903428970" "Revista" => array:6 [ "tituloSerie" => "Int J Neurosci" "fecha" => "2010" "volumen" => "120" "paginaInicial" => "71" "paginaFinal" => "75" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20128675" "web" => "Medline" ] ] ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0070" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromielitis optica: a pilot study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Araki" 1 => "T. Matsuoka" 2 => "K. Miyamoto" 3 => "S. Kusunoki" 4 => "T. Okamoto" 5 => "M. Murata" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1212/WNL.0000000000000317" "Revista" => array:7 [ "tituloSerie" => "Neurology" "fecha" => "2014" "volumen" => "82" "paginaInicial" => "1302" "paginaFinal" => "1306" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24634453" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S001078241730478X" "estado" => "S300" "issn" => "00107824" ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0075" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "G. Jones" 1 => "C. Ding" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4137/CMAMD.S4864" "Revista" => array:6 [ "tituloSerie" => "Clin Med Insights Arthritis Musculoskelet Disord" "fecha" => "2010" "volumen" => "3" "paginaInicial" => "81" "paginaFinal" => "89" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21234291" "web" => "Medline" ] ] ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0080" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica implication for cellular immune responses" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "B.C. Kieseier" 1 => "O. Stüve" 2 => "T. Dehmel" 3 => "N. Goebels" 4 => "V.I. Leussink" 5 => "A.K. Mausberg" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamaneurol.2013.668" "Revista" => array:6 [ "tituloSerie" => "JAMA Neurol" "fecha" => "2013" "volumen" => "70" "paginaInicial" => "390" "paginaFinal" => "393" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23599943" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0085" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.M. Wingerchuk" 1 => "B. Banwell" 2 => "J.L. Bennett" 3 => "P. Cabre" 4 => "W. Carroll" 5 => "T. Chitnis" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1212/WNL.0000000000001729" "Revista" => array:7 [ "tituloSerie" => "Neurology" "fecha" => "2015" "volumen" => "85" "paginaInicial" => "177" "paginaFinal" => "189" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26092914" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0010782415301396" "estado" => "S300" "issn" => "00107824" ] ] ] ] ] ] ] 17 => array:3 [ "identificador" => "bib0090" "etiqueta" => "18" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "M. Araki" 1 => "T. Aranami" 2 => "T. Matsuoka" 3 => "M. Nakamura" 4 => "S. Miyake" 5 => "T. Yamamura" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10165-012-0715-9" "Revista" => array:6 [ "tituloSerie" => "Mod Rheumatol" "fecha" => "2013" "volumen" => "23" "paginaInicial" => "827" "paginaFinal" => "831" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22782533" "web" => "Medline" ] ] ] ] ] ] ] ] 18 => array:3 [ "identificador" => "bib0095" "etiqueta" => "19" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "I. Ayzenberg" 1 => "I. Kleiter" 2 => "A. Schroder" 3 => "K. Hellwig" 4 => "A. Chan" 5 => "T. Yamamura" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamaneurol.2013.1246" "Revista" => array:6 [ "tituloSerie" => "JAMA Neurol" "fecha" => "2013" "volumen" => "70" "paginaInicial" => "394" "paginaFinal" => "397" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23358868" "web" => "Medline" ] ] ] ] ] ] ] ] 19 => array:3 [ "identificador" => "bib0100" "etiqueta" => "20" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.S. Lauenstein" 1 => "M. Stettner" 2 => "B.C. Kieseier" 3 => "E. Lensch" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Case Rep" "fecha" => "2014" "volumen" => "26" "paginaInicial" => "2014" ] ] ] ] ] ] 20 => array:3 [ "identificador" => "bib0105" "etiqueta" => "21" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Ringelstein" 1 => "I. Ayzenberg" 2 => "J. Harmel" 3 => "A.S. Lauenstein" 4 => "E. Lensch" 5 => "F. Stogbauer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/jamaneurol.2015.0533" "Revista" => array:6 [ "tituloSerie" => "JAMA Neurol" "fecha" => "2015" "volumen" => "72" "paginaInicial" => "756" "paginaFinal" => "776" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25985228" "web" => "Medline" ] ] ] ] ] ] ] ] 21 => array:3 [ "identificador" => "bib0110" "etiqueta" => "22" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of neuromyelitis optica: current debate" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "T. Okamoto" 1 => "M. Ogawa" 2 => "Y. Lin" 3 => "M. Murata" 4 => "S. Miyake" 5 => "T. Yamamura" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1177/1756285608093978" "Revista" => array:6 [ "tituloSerie" => "Ther Adv Neurol Disord" "fecha" => "2008" "volumen" => "1" "paginaInicial" => "5" "paginaFinal" => "12" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21180560" "web" => "Medline" ] ] ] ] ] ] ] ] 22 => array:3 [ "identificador" => "bib0115" "etiqueta" => "23" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Failure of natalizumab to prevent relapses in neuromyelitis optica" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "Neuromyelitis Optica Study Group" "etal" => true "autores" => array:6 [ 0 => "I. Kleiter" 1 => "K. Hellwig" 2 => "A. Berthele" 3 => "T. Kümpfel" 4 => "R.A. Linker" 5 => "H.P. Hartung" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archneurol.2011.216" "Revista" => array:6 [ "tituloSerie" => "Arch Neurol" "fecha" => "2012" "volumen" => "69" "paginaInicial" => "239" "paginaFinal" => "245" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22332191" "web" => "Medline" ] ] ] ] ] ] ] ] 23 => array:3 [ "identificador" => "bib0120" "etiqueta" => "24" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "OPTION Investigators" "etal" => true "autores" => array:6 [ 0 => "J.S. Smolen" 1 => "A. Beaulieu" 2 => "A. Rubbert-Roth" 3 => "C. Ramos-Remus" 4 => "J. Rovensky" 5 => "E. Alecock" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(08)60453-5" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2008" "volumen" => "371" "paginaInicial" => "987" "paginaFinal" => "997" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18358926" "web" => "Medline" ] ] ] ] ] ] ] ] 24 => array:3 [ "identificador" => "bib0125" "etiqueta" => "25" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A. Ogata" 1 => "T. Hirano" 2 => "Y. Hishitani" 3 => "T. Tanaka" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.4137/CMAMD.S7371" "Revista" => array:7 [ "tituloSerie" => "Clin Med Insights Arthritis Musculoskelet Disord" "fecha" => "2012" "volumen" => "5" "paginaInicial" => "27" "paginaFinal" => "42" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22438671" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0010782414000353" "estado" => "S300" "issn" => "00107824" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/21735808/0000003700000003/v1_202204220526/S2173580821000237/v1_202204220526/en/main.assets" "Apartado" => array:4 [ "identificador" => "9491" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original Articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/21735808/0000003700000003/v1_202204220526/S2173580821000237/v1_202204220526/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580821000237?idApp=UINPBA00004N"]

Statistics

Original article

Experiencia con tocilizumab en pacientes con espectro de la neuromielitis óptica

E. Carreón Guarnizoa,b,

Corresponding author

strcg_2@hotmail.com

Corresponding author.

, R. Hernández Claresa,b, T. Castillo Triviñoc, V. Meca Lallanad, V. Arocas Casañe, F. Iniesta Martínezb, J. Olascoaga Urtazac, J.E. Meca Lallanaa,b

a CSUR Esclerosis Múltiple y Unidad de Neuroinmunología Clínica, Servicio de Neurología, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain

b Cátedra de Neuroinmunología Clínica y Esclerosis Múltiple, UCAM, Universidad Católica San Antonio, Murcia, Spain

c Unidad de Esclerosis Múltiple, Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, Spain

d Unidad de Esclerosis Múltiple, Servicio de Neurología, Hospital Universitario de La Princesa, Madrid, Spain

e Servicio de Farmacia, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain

Read

1876

Times
was read the article

444

Total PDF

1432

Total HTML

Share statistics

 array:25 [
  "pii" => "S2173580821000237"
  "issn" => "21735808"
  "doi" => "10.1016/j.nrleng.2018.12.021"
  "estado" => "S300"
  "fechaPublicacion" => "2022-04-01"
  "aid" => "1289"
  "copyright" => "Sociedad Espa&#241;ola de Neurolog&#237;a"
  "copyrightAnyo" => "2019"
  "documento" => "article"
  "crossmark" => 1
  "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
  "subdocumento" => "fla"
  "cita" => "Neurologia. 2022;37:178-83"
  "abierto" => array:3 [
    "ES" => true
    "ES2" => true
    "LATM" => true
  ]
  "gratuito" => true
  "lecturas" => array:1 [
    "total" => 0
  ]
  "Traduccion" => array:1 [
    "es" => array:20 [
      "pii" => "S0213485319300337"
      "issn" => "02134853"
      "doi" => "10.1016/j.nrl.2018.12.013"
      "estado" => "S300"
      "fechaPublicacion" => "2022-04-01"
      "aid" => "1289"
      "copyright" => "Sociedad Espa&#241;ola de Neurolog&#237;a"
      "documento" => "article"
      "crossmark" => 1
      "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
      "subdocumento" => "fla"
      "cita" => "Neurologia. 2022;37:178-83"
      "abierto" => array:3 [
        "ES" => true
        "ES2" => true
        "LATM" => true
      ]
      "gratuito" => true
      "lecturas" => array:2 [
        "total" => 889
        "formatos" => array:3 [
          "EPUB" => 54
          "HTML" => 440
          "PDF" => 395
        ]
      ]
      "es" => array:12 [
        "idiomaDefecto" => true
        "cabecera" => "<span class="elsevierStyleTextfn">ORIGINAL</span>"
        "titulo" => "Experiencia con tocilizumab en pacientes con espectro de la neuromielitis &#243;ptica"
        "tienePdf" => "es"
        "tieneTextoCompleto" => "es"
        "tieneResumen" => array:2 [
          0 => "es"
          1 => "en"
        ]
        "paginas" => array:1 [
          0 => array:2 [
            "paginaInicial" => "178"
            "paginaFinal" => "183"
          ]
        ]
        "titulosAlternativos" => array:1 [
          "en" => array:1 [
            "titulo" => "Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders"
          ]
        ]
        "contieneResumen" => array:2 [
          "es" => true
          "en" => true
        ]
        "contieneTextoCompleto" => array:1 [
          "es" => true
        ]
        "contienePdf" => array:1 [
          "es" => true
        ]
        "autores" => array:1 [
          0 => array:2 [
            "autoresLista" => "E&#46; Carre&#243;n Guarnizo, R&#46; Hern&#225;ndez Clares, T&#46; Castillo Trivi&#241;o, V&#46; Meca Lallana, V&#46; Arocas Casa&#241;, F&#46; Iniesta Mart&#237;nez, J&#46; Olascoaga Urtaza, J&#46;E&#46; Meca Lallana"
            "autores" => array:8 [
              0 => array:2 [
                "nombre" => "E&#46;"
                "apellidos" => "Carre&#243;n Guarnizo"
              ]
              1 => array:2 [
                "nombre" => "R&#46;"
                "apellidos" => "Hern&#225;ndez Clares"
              ]
              2 => array:2 [
                "nombre" => "T&#46;"
                "apellidos" => "Castillo Trivi&#241;o"
              ]
              3 => array:2 [
                "nombre" => "V&#46;"
                "apellidos" => "Meca Lallana"
              ]
              4 => array:2 [
                "nombre" => "V&#46;"
                "apellidos" => "Arocas Casa&#241;"
              ]
              5 => array:2 [
                "nombre" => "F&#46;"
                "apellidos" => "Iniesta Mart&#237;nez"
              ]
              6 => array:2 [
                "nombre" => "J&#46;"
                "apellidos" => "Olascoaga Urtaza"
              ]
              7 => array:2 [
                "nombre" => "J&#46;E&#46;"
                "apellidos" => "Meca Lallana"
              ]
            ]
          ]
        ]
      ]
      "idiomaDefecto" => "es"
      "Traduccion" => array:1 [
        "en" => array:9 [
          "pii" => "S2173580821000237"
          "doi" => "10.1016/j.nrleng.2018.12.021"
          "estado" => "S300"
          "subdocumento" => ""
          "abierto" => array:3 [
            "ES" => true
            "ES2" => true
            "LATM" => true
          ]
          "gratuito" => true
          "lecturas" => array:1 [
            "total" => 0
          ]
          "idiomaDefecto" => "en"
          "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580821000237?idApp=UINPBA00004N"
        ]
      ]
      "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485319300337?idApp=UINPBA00004N"
      "url" => "/02134853/0000003700000003/v1_202203290758/S0213485319300337/v1_202203290758/es/main.assets"
    ]
  ]
  "itemSiguiente" => array:20 [
    "pii" => "S2173580821000225"
    "issn" => "21735808"
    "doi" => "10.1016/j.nrleng.2018.12.020"
    "estado" => "S300"
    "fechaPublicacion" => "2022-04-01"
    "aid" => "1288"
    "copyright" => "Sociedad Espa&#241;ola de Neurolog&#237;a"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Neurologia. 2022;37:184-91"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "Ischaemic stroke as a complication of cardiac catheterisation&#46; Clinical and radiological characteristics&#44; progression&#44; and therapeutic implications"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "184"
          "paginaFinal" => "191"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Ictus isqu&#233;mico como complicaci&#243;n del cateterismo card&#237;aco&#46; Caracter&#237;sticas cl&#237;nicas&#44; radiol&#243;gicas y evolutivas e implicaciones terap&#233;uticas"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 1192
              "Ancho" => 2083
              "Tamanyo" => 172562
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Flow chart illustrating the patient selection process&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "L&#46; Mart&#237;n-Aguilar, M&#46; Par&#233;-Curell, L&#46; Dorado, N&#46; P&#233;rez de la Ossa-Herrero, A&#46; Ramos-Pach&#243;n, E&#46; L&#243;pez-Cancio, E&#46; Fern&#225;ndez-Nofrerias, O&#46; Rodr&#237;guez-Leor, C&#46; Casta&#241;o, S&#46; Remollo, P&#46; Puyalto, P&#46; Cuadras, M&#46; Mill&#225;n, A&#46; D&#225;valos, M&#46; Hern&#225;ndez-P&#233;rez"
          "autores" => array:15 [
            0 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Mart&#237;n-Aguilar"
            ]
            1 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Par&#233;-Curell"
            ]
            2 => array:2 [
              "nombre" => "L&#46;"
              "apellidos" => "Dorado"
            ]
            3 => array:2 [
              "nombre" => "N&#46;"
              "apellidos" => "P&#233;rez de la Ossa-Herrero"
            ]
            4 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Ramos-Pach&#243;n"
            ]
            5 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "L&#243;pez-Cancio"
            ]
            6 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Fern&#225;ndez-Nofrerias"
            ]
            7 => array:2 [
              "nombre" => "O&#46;"
              "apellidos" => "Rodr&#237;guez-Leor"
            ]
            8 => array:2 [
              "nombre" => "C&#46;"
              "apellidos" => "Casta&#241;o"
            ]
            9 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Remollo"
            ]
            10 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Puyalto"
            ]
            11 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Cuadras"
            ]
            12 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Mill&#225;n"
            ]
            13 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "D&#225;valos"
            ]
            14 => array:2 [
              "nombre" => "M&#46;"
              "apellidos" => "Hern&#225;ndez-P&#233;rez"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0213485319300325"
        "doi" => "10.1016/j.nrl.2018.12.012"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485319300325?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580821000225?idApp=UINPBA00004N"
    "url" => "/21735808/0000003700000003/v1_202204220526/S2173580821000225/v1_202204220526/en/main.assets"
  ]
  "itemAnterior" => array:20 [
    "pii" => "S2173580821000444"
    "issn" => "21735808"
    "doi" => "10.1016/j.nrleng.2019.03.017"
    "estado" => "S300"
    "fechaPublicacion" => "2022-04-01"
    "aid" => "1295"
    "copyright" => "Sociedad Espa&#241;ola de Neurolog&#237;a"
    "documento" => "article"
    "crossmark" => 1
    "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/"
    "subdocumento" => "fla"
    "cita" => "Neurologia. 2022;37:171-7"
    "abierto" => array:3 [
      "ES" => true
      "ES2" => true
      "LATM" => true
    ]
    "gratuito" => true
    "lecturas" => array:1 [
      "total" => 0
    ]
    "en" => array:13 [
      "idiomaDefecto" => true
      "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
      "titulo" => "Epilepsy in elderly patients&#58; does age of onset make a difference&#63;"
      "tienePdf" => "en"
      "tieneTextoCompleto" => "en"
      "tieneResumen" => array:2 [
        0 => "en"
        1 => "es"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "171"
          "paginaFinal" => "177"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "es" => array:1 [
          "titulo" => "Epilepsia en el anciano&#58; &#191;la edad de inicio marca la diferencia&#63;"
        ]
      ]
      "contieneResumen" => array:2 [
        "en" => true
        "es" => true
      ]
      "contieneTextoCompleto" => array:1 [
        "en" => true
      ]
      "contienePdf" => array:1 [
        "en" => true
      ]
      "resumenGrafico" => array:2 [
        "original" => 0
        "multimedia" => array:8 [
          "identificador" => "fig0005"
          "etiqueta" => "Figure 1"
          "tipo" => "MULTIMEDIAFIGURA"
          "mostrarFloat" => true
          "mostrarDisplay" => false
          "figura" => array:1 [
            0 => array:4 [
              "imagen" => "gr1.jpeg"
              "Alto" => 983
              "Ancho" => 2122
              "Tamanyo" => 111896
            ]
          ]
          "detalles" => array:1 [
            0 => array:3 [
              "identificador" => "at0005"
              "detalle" => "Figure "
              "rol" => "short"
            ]
          ]
          "descripcion" => array:1 [
            "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Number of elderly patients in groups A &#40;disease onset before 65 years of age&#41; and B &#40;onset at or after 65 years&#41; in whom different antiepileptic drugs were tried and who continued treatment with these drugs &#40;results are expressed as absolute numbers&#41;&#46; Mean doses &#40;mg&#47;24&#8239;h&#41; with standard deviations and ranges &#40;mg&#47;24&#8239;h&#41; are also indicated&#46;</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">CBZ&#58; carbamazepine&#59; CLB&#58; clobazam&#59; ESL&#58; eslicarbazepine&#59; GBT&#58; gabapentin&#59; LCS&#58; lacosamide&#59; LEV&#58; levetiracetam&#59; LTG&#58; lamotrigine&#59; OXC&#58; oxcarbazepine&#59; PB&#58; phenobarbital&#59; PGB&#58; pregabalin&#59; PHT&#58; phenytoin&#59; PRM&#58; primidone&#59; RFN&#58; rufinamide&#59; TPM&#58; topiramate&#59; VPA&#58; valproic acid&#59; ZNS&#58; zonisamide&#46;</p>"
          ]
        ]
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "A&#46; Suller Marti, E&#46; Bellosta Diago, P&#46; Vinueza Buitron, A&#46; Vel&#225;zquez Benito, S&#46; Santos Lasaosa, J&#46;&#193;&#46; Mauri Llerda"
          "autores" => array:6 [
            0 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Suller Marti"
            ]
            1 => array:2 [
              "nombre" => "E&#46;"
              "apellidos" => "Bellosta Diago"
            ]
            2 => array:2 [
              "nombre" => "P&#46;"
              "apellidos" => "Vinueza Buitron"
            ]
            3 => array:2 [
              "nombre" => "A&#46;"
              "apellidos" => "Vel&#225;zquez Benito"
            ]
            4 => array:2 [
              "nombre" => "S&#46;"
              "apellidos" => "Santos Lasaosa"
            ]
            5 => array:2 [
              "nombre" => "J&#46;&#193;&#46;"
              "apellidos" => "Mauri Llerda"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "en"
    "Traduccion" => array:1 [
      "es" => array:9 [
        "pii" => "S0213485319300453"
        "doi" => "10.1016/j.nrl.2019.03.001"
        "estado" => "S300"
        "subdocumento" => ""
        "abierto" => array:3 [
          "ES" => true
          "ES2" => true
          "LATM" => true
        ]
        "gratuito" => true
        "lecturas" => array:1 [
          "total" => 0
        ]
        "idiomaDefecto" => "es"
        "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0213485319300453?idApp=UINPBA00004N"
      ]
    ]
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580821000444?idApp=UINPBA00004N"
    "url" => "/21735808/0000003700000003/v1_202204220526/S2173580821000444/v1_202204220526/en/main.assets"
  ]
  "en" => array:19 [
    "idiomaDefecto" => true
    "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>"
    "titulo" => "Experience with tocilizumab in patients with neuromyelitis optica spectrum disorders"
    "tieneTextoCompleto" => true
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "178"
        "paginaFinal" => "183"
      ]
    ]
    "autores" => array:1 [
      0 => array:4 [
        "autoresLista" => "E&#46; Carre&#243;n Guarnizo, R&#46; Hern&#225;ndez Clares, T&#46; Castillo Trivi&#241;o, V&#46; Meca Lallana, V&#46; Arocas Casa&#241;, F&#46; Iniesta Mart&#237;nez, J&#46; Olascoaga Urtaza, J&#46;E&#46; Meca Lallana"
        "autores" => array:8 [
          0 => array:4 [
            "nombre" => "E&#46;"
            "apellidos" => "Carre&#243;n Guarnizo"
            "email" => array:1 [
              0 => "strcg_2@hotmail.com"
            ]
            "referencia" => array:3 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
              2 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">&#42;</span>"
                "identificador" => "cor0005"
              ]
            ]
          ]
          1 => array:3 [
            "nombre" => "R&#46;"
            "apellidos" => "Hern&#225;ndez Clares"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          2 => array:3 [
            "nombre" => "T&#46;"
            "apellidos" => "Castillo Trivi&#241;o"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          3 => array:3 [
            "nombre" => "V&#46;"
            "apellidos" => "Meca Lallana"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">d</span>"
                "identificador" => "aff0020"
              ]
            ]
          ]
          4 => array:3 [
            "nombre" => "V&#46;"
            "apellidos" => "Arocas Casa&#241;"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">e</span>"
                "identificador" => "aff0025"
              ]
            ]
          ]
          5 => array:3 [
            "nombre" => "F&#46;"
            "apellidos" => "Iniesta Mart&#237;nez"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
          6 => array:3 [
            "nombre" => "J&#46;"
            "apellidos" => "Olascoaga Urtaza"
            "referencia" => array:1 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">c</span>"
                "identificador" => "aff0015"
              ]
            ]
          ]
          7 => array:3 [
            "nombre" => "J&#46;E&#46;"
            "apellidos" => "Meca Lallana"
            "referencia" => array:2 [
              0 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">a</span>"
                "identificador" => "aff0005"
              ]
              1 => array:2 [
                "etiqueta" => "<span class="elsevierStyleSup">b</span>"
                "identificador" => "aff0010"
              ]
            ]
          ]
        ]
        "afiliaciones" => array:5 [
          0 => array:3 [
            "entidad" => "CSUR Esclerosis M&#250;ltiple y Unidad de Neuroinmunolog&#237;a Cl&#237;nica&#44; Servicio de Neurolog&#237;a&#44; Hospital Cl&#237;nico Universitario Virgen de la Arrixaca&#44; IMIB-Arrixaca&#44; Murcia&#44; Spain"
            "etiqueta" => "a"
            "identificador" => "aff0005"
          ]
          1 => array:3 [
            "entidad" => "C&#225;tedra de Neuroinmunolog&#237;a Cl&#237;nica y Esclerosis M&#250;ltiple&#44; UCAM&#44; Universidad Cat&#243;lica San Antonio&#44; Murcia&#44; Spain"
            "etiqueta" => "b"
            "identificador" => "aff0010"
          ]
          2 => array:3 [
            "entidad" => "Unidad de Esclerosis M&#250;ltiple&#44; Servicio de Neurolog&#237;a&#44; Hospital Universitario Donostia&#44; San Sebasti&#225;n&#44; Spain"
            "etiqueta" => "c"
            "identificador" => "aff0015"
          ]
          3 => array:3 [
            "entidad" => "Unidad de Esclerosis M&#250;ltiple&#44; Servicio de Neurolog&#237;a&#44; Hospital Universitario de La Princesa&#44; Madrid&#44; Spain"
            "etiqueta" => "d"
            "identificador" => "aff0020"
          ]
          4 => array:3 [
            "entidad" => "Servicio de Farmacia&#44; Hospital Cl&#237;nico Universitario Virgen de la Arrixaca&#44; IMIB-Arrixaca&#44; Murcia&#44; Spain"
            "etiqueta" => "e"
            "identificador" => "aff0025"
          ]
        ]
        "correspondencia" => array:1 [
          0 => array:3 [
            "identificador" => "cor0005"
            "etiqueta" => "&#8270;"
            "correspondencia" => "Corresponding author&#46;"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "es" => array:1 [
        "titulo" => "Experiencia con tocilizumab en pacientes con espectro de la neuromielitis &#243;ptica"
      ]
    ]
    "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Neuromyelitis optica spectrum disorders &#40;NMOSD&#41; are inflammatory diseases of the central nervous system&#59; the main pathogenic mechanism is mediated by the action of aquaporin-4 antibodies &#40;AQP4-IgG&#41;&#44; which target aquaporin-4 channels &#40;AQP4&#41;&#44; the most abundant water channels in the central nervous system&#46; The clinical course includes recurrent outbreaks &#40;only 5&#37;-10&#37; are monophasic&#41; of optic neuritis or transverse myelitis&#44; although today the disease is considered to affect not only the optic nerves and the spinal cord&#44; as initially described&#44; but also the brainstem and brain hemispheres&#46; Outbreaks are usually severe and the risk of disabling sequelae is high&#46;<a class="elsevierStyleCrossRef" href="#bib0005"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Immunosuppressants are the main disease-modifying treatments &#40;DMT&#41; used&#59; however&#44; no randomised controlled clinical trial has provided a sufficient level of evidence to conclusively support the use of any specific drug&#46; The low incidence of the disease&#44; together with the availability of effective treatment options&#44; probably further decreases the number of cases available to be included in placebo-controlled trials&#46; In clinical practice&#44; therapeutic management is supported by results from small series of patients receiving different immunosuppressants&#46; Although optimal responses to such treatments as azathioprine&#44; mycophenolate mofetil&#44; methotrexate&#44; and mitoxantrone have been reported&#44; the best outcomes were obtained with rituximab &#40;RTX&#41;&#44; a monoclonal antibody targeting the CD20 antigen of B cells&#44; which has obtained response rates between 50&#37; and 93&#37;&#46;<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2&#8211;8</span></a> The meta-analysis by Damto et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">9</span></a> which included 46 studies &#40;<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>&#61;<span class="elsevierStyleHsp" style=""></span>438&#41; of patients with NMOSD and treated with RTX&#44; showed that RTX is an effective treatment for reducing relapses&#59; however&#44; due to the lack of controlled studies with results on safety&#44; it should be used with caution as a first option&#46; In spite of these results&#44; between 7&#37; and 47&#37; of patients treated with RTX&#44; according to different series&#44; may present relapses&#44; even with complete depletion of B cells&#46;<a class="elsevierStyleCrossRefs" href="#bib0010"><span class="elsevierStyleSup">2&#8211;8</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">Different studies on the pathogenesis of NMOSD have reported significantly higher levels of proinflammatory interleukin 6 &#40;IL-6&#41; in serum and cerebrospinal fluid than in other autoimmune neurological diseases&#44;<a class="elsevierStyleCrossRefs" href="#bib0050"><span class="elsevierStyleSup">10&#44;11</span></a> which may mean that IL-6 has a relevant pathogenic role in these disorders&#46; IL-6 would prolong the survival of certain B cell subclasses and the secretion of anti-AQP4 antibodies&#46;<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">12&#8211;14</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Tocilizumab is a recombinant humanised monoclonal IgG1 antibody targeting the human IL-6 receptor&#46; It is indicated as treatment for rheumatoid arthritis&#44; and is dosed at 8<span class="elsevierStyleHsp" style=""></span>mg&#47;kg body weight&#44; administered intravenously every 4 weeks&#46; Tocilizumab has been shown to be effective in other autoimmune diseases&#44; such as systemic lupus erythematosus&#46;<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">15</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Some studies using tocilizumab to treat NMOSD have shown decreased intrathecal levels of IL-6 in the cerebrospinal fluid&#44; which are correlated with decreased disease activity&#44; both clinically and in imaging studies&#46;<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">16</span></a> Tocilizumab may be beneficial for treatment of some of the most frequent symptoms&#44; such as fatigue and neuropathic pain&#46;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Material and methods</span><p id="par0030" class="elsevierStylePara elsevierViewall">The aim of the study is to assess the effectiveness and safety of treatment with tocilizumab in patients with NMOSD who have not previously responded to other DMTs&#46;</p><p id="par0035" class="elsevierStylePara elsevierViewall">This is an observational study including a retrospective analysis of a series of patients diagnosed with NMOSD at 3 reference hospitals for inflammatory and demyelinating diseases of the central nervous system&#46; Inclusion criteria were&#58; diagnosis of NMOSD according to the criteria proposed by Wingerchuck et al&#46;<a class="elsevierStyleCrossRef" href="#bib0085"><span class="elsevierStyleSup">17</span></a> in 2015&#44; previous ineffectiveness of one or several DMTs&#44; and having used tocilizumab dosed at 8<span class="elsevierStyleHsp" style=""></span>mg&#47;kg body weight every 4 weeks after suspension of the last DMT due to lack of therapeutic response&#46;</p><p id="par0040" class="elsevierStylePara elsevierViewall">Lack of response to a previous DMT was defined as the presence of a clinical relapse &#40;optic neuropathy&#44; myelitis&#44; or brainstem syndrome&#41; during exposure to the drug&#46;</p><p id="par0045" class="elsevierStylePara elsevierViewall">We retrospectively gathered demographic data and information on disease progression from diagnosis of NMOSD to the time of drafting this study&#59; therefore&#44; tocilizumab exposure time is different in each patient&#46; After being diagnosed&#44; patients were periodically assessed by a neurologist specialising in demyelinating diseases&#46;</p><p id="par0050" class="elsevierStylePara elsevierViewall">The primary outcome variable was the annualised relapse rate &#40;ARR&#41;&#44; determined by dividing the total number of relapses by a period of time in years&#44; and calculated before and after each treatment&#46; Secondary variables were the degree of disability&#44; radiological progression in magnetic resonance imaging &#40;MRI&#41; studies&#44; and the degree of tolerance and safety&#46;</p><p id="par0055" class="elsevierStylePara elsevierViewall">To quantify the degree of disability we used the Expanded Disability Status Scale &#40;EDSS&#41;&#44; which is frequently used in multiple sclerosis&#46; We collected all the data on brain and spinal MRI available during clinical follow-up&#44; analysing gadolinium-enhanced T2-weighted&#44; FLAIR&#44; and T1-weighted sequences&#46; We also analysed all the laboratory and clinical results related to safety from tocilizumab treatment onset&#46;</p><p id="par0060" class="elsevierStylePara elsevierViewall">Differences between quantitative variables were measured with the paired samples <span class="elsevierStyleItalic">t</span> test&#46;</p><p id="par0065" class="elsevierStylePara elsevierViewall">Patients signed informed consent forms and the drug was administered after its approval by the corresponding regulatory body as an off-label treatment&#46;</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Results</span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Demographic and baseline clinical characteristics</span><p id="par0070" class="elsevierStylePara elsevierViewall">Of all the patients with NMOSD analysed&#44; we identified 5 who met the inclusion criteria&#46; Three patients &#40;60&#37;&#41; were women&#46; Mean age &#40;SD&#41; at diagnosis was 50 &#40;5&#46;3&#41; years&#44; and all patients had presented at least one episode of optic neuritis and one episode of longitudinally extensive transverse myelitis&#46; No patient presented comorbid autoimmune diseases&#46; Two patients presented AQP4-IgG in serum and none presented MOG-IgG&#46; The transfected cell technique was used to quantify AQP4-IgG antibodies&#46;</p><p id="par0075" class="elsevierStylePara elsevierViewall">As is required for other conditions treated with tocilizumab&#44; latent tuberculosis and active infections were ruled out before treatment onset&#46; No specific washout period was established &#40;the minimum time elapsed was 6 months&#41;&#44; but titres of total leukocytes&#44; lymphocytes&#44; neutrophils&#44; and platelets had to be within the normal range before treatment administration&#46;</p><p id="par0080" class="elsevierStylePara elsevierViewall">All patients had received RTX as a DMT at some point during progression &#40;dosed at 375<span class="elsevierStyleHsp" style=""></span>mg&#47;m<span class="elsevierStyleSup">2</span> weekly for 4 weeks and a minimum of 1<span class="elsevierStyleHsp" style=""></span>g after one year&#41;&#46; Two had also been treated with cyclophosphamide and one with azathioprine&#46; One patient had been previously diagnosed with multiple sclerosis and received sequential treatment with interferon beta and natalizumab before diagnosis of NMOSD&#46;</p><p id="par0085" class="elsevierStylePara elsevierViewall">Despite the DMTs administered&#44; patients presented a mean ARR &#40;SD&#41; of 1&#46;8 &#40;1&#46;3&#41; in the year prior to tocilizumab treatment onset and a mean EDSS score of 5&#46;3 &#40;2&#41;&#46; At baseline &#40;before starting on tocilizumab&#41;&#44; 4 of the 5 patients &#40;80&#37;&#41; presented considerable disease activity in terms of number and severity of relapses &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Effectiveness and safety of tocilizumab</span><p id="par0090" class="elsevierStylePara elsevierViewall">Mean duration &#40;SD&#41; of treatment with tocilizumab was 2&#46;3 &#40;1&#41; years&#46; After tocilizumab was started&#44; a drastic reduction was observed in the number of relapses&#59; in fact&#44; 4 &#40;80&#37;&#41; patients did not experience relapses during follow-up&#46; The only relapse observed&#44; at 3 months after starting tocilizumab &#40;patient 5&#44; <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41; consisted of cervical myelitis with sensory involvement of the lower limbs&#44; which completely resolved after a megadose of steroids&#46; Although follow-up periods for treatment with tocilizumab were variable&#44; all patients completed a minimum of one year &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46; During the first year of treatment&#44; ARRs decreased by 88&#46;9&#37; with regard to the previous year &#40;1&#46;8 &#91;1&#46;3&#93; vs 0&#46;2 &#91;0&#46;4&#93;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;05&#41;&#44; and no significant variations were observed in the degree of disability as measured with the EDSS &#40;5&#46;3 &#91;2&#93; vs 5&#46;2 &#91;1&#46;9&#93;&#59; <span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#62;<span class="elsevierStyleHsp" style=""></span>&#46;05&#41;&#46;</p><p id="par0095" class="elsevierStylePara elsevierViewall">We analysed follow-up MRI scans performed the year after starting tocilizumab &#40;mean time after treatment onset&#58; 8&#46;6 &#91;3&#46;1&#93; months&#41; and compared the results with the last available MRI from the year prior&#46; No changes were observed between brain MRI studies&#46; No patient presented new lesions on spinal cord T2-weighted sequences&#46; The 2 patients with gadolinium-enhancing &#40;Gd&#43;&#41; active spinal cord lesions presented reductions greater than 75&#37; in the Gd&#43; area &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#41;&#46;</p><p id="par0100" class="elsevierStylePara elsevierViewall">The most relevant adverse events were one case of asymptomatic mild neutropaenia of 6 months&#8217; duration &#40;with subsequent spontaneous resolution&#41; and one case of chronic urinary tract infection &#40;already observed with previous DMT&#41; in another patient&#46;</p><p id="par0105" class="elsevierStylePara elsevierViewall">AQP4-IgG and IL-6 levels were not quantified during follow-up&#46;</p></span></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Discussion</span><p id="par0110" class="elsevierStylePara elsevierViewall">Considering that NMOSD relapses are frequently disabling and present a high risk of sequelae&#44; starting immunosuppressive DMT is essential for preventing recurrence&#46; Currently&#44; due to the lack of randomised clinical trials on the treatment of NMOSD&#44; the available evidence is insufficient to recommend a specific immunosuppressive treatment&#59; therefore&#44; clinical experience takes on special relevance&#46;</p><p id="par0115" class="elsevierStylePara elsevierViewall">The patient series reported to date have shown the effectiveness of tocilizumab in reducing the rate of relapses&#44; without relevant adverse effects&#59; however&#44; these studies generally present isolated cases and small series of patients showing resistance to other treatments&#46;<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14&#44;16&#44;18&#8211;20</span></a></p><p id="par0120" class="elsevierStylePara elsevierViewall">One of the largest series&#44; including 7 patients&#44;<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">14</span></a> showed that treatment with tocilizumab in NMOSD reduces the ARR and improves EDSS score &#40;level of evidence IV&#41;&#46; Although the majority of patients receiving tocilizumab presented aggressive disease refractory to treatment with anti-CD20 antibodies&#44; we suggest that the drug should be considered at earlier stages of NMOSD to improve patients&#8217; quality of life&#46; The series reported by Ringelstein et al&#46;&#44;<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">21</span></a> including 8 patients&#44; showed the effectiveness and safety of tocilizumab&#44; especially in patients presenting inadequate response to RTX&#46; Both series<a class="elsevierStyleCrossRefs" href="#bib0070"><span class="elsevierStyleSup">14&#44;21</span></a> showed improvements in radiological activity &#40;Gd&#43;&#41;&#44; in addition to decreases in EDSS scores and antibody titres &#40;AQP4-IgG&#41; during treatment&#46; Both studies reported a decrease in relapse frequency and intensity &#40;mild-moderate&#41;&#44; with patients presenting resolution without sequelae&#46; Neither reported severe adverse events&#46;</p><p id="par0125" class="elsevierStylePara elsevierViewall">Our results are similar to those reported in other series in terms of the decrease in ARRs&#44; the absence of progression of disability&#44; the absence of new MRI lesions&#44; and the radiological improvement in patients with Gd&#43; lesions&#46;</p><p id="par0130" class="elsevierStylePara elsevierViewall">Several studies have suggested that the administration of treatments indicated for multiple sclerosis &#40;such as natalizumab&#41; in patients with NMOSD does not provide any benefit for any clinical or radiological variable&#44; and may even lead to poorer results in these parameters&#59; therefore&#44; their use is not recommended&#46;<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">20&#44;22&#44;23</span></a> In our series&#44; one patient had been treated sequentially with interferon beta and natalizumab before diagnosis of NMOSD&#44; and during that period he presented numerous episodes of optic neuropathy&#44; resulting in severely impaired residual visual acuity &#40;<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>&#44; patient 3&#41;&#46;</p><p id="par0135" class="elsevierStylePara elsevierViewall">Patients treated with tocilizumab for rheumatoid arthritis have been reported to present a higher risk of infection&#44; mainly urinary tract infections and reactivation of latent tuberculosis&#46;<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">24</span></a> However&#44; a low percentage of severe infections is reported in these patients at 5 years of treatment&#44; which shows that tocilizumab has a good long-term safety profile&#46;<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">25</span></a> The patients included in our series presented good tolerance to tocilizumab&#44; and presented few adverse effects of any kind&#46; We can mention one case of transient neutropaenia that did not lead to any secondary opportunistic infection&#46;</p><p id="par0140" class="elsevierStylePara elsevierViewall">Our results&#44; like those of previous studies&#44; are characterised by good response to tocilizumab in aggressive&#44; refractory NMOSD&#44; which raises the question of the drug&#39;s potential effectiveness as a first-line DMT&#46; At the time of writing&#44; we are aware of an ongoing phase 3 clinical trial with the molecule SA237&#44; an anti&#8211;IL-6 receptor monoclonal antibody&#46;</p><p id="par0145" class="elsevierStylePara elsevierViewall">The main limitations of our study are its observational&#44; retrospective design and the possible influence of regression toward the mean in the improvement in ARRs&#44; although the good radiological findings lead us to suspect a limited influence&#46;</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Conclusions</span><p id="par0150" class="elsevierStylePara elsevierViewall">In our experience&#44; tocilizumab &#40;8<span class="elsevierStyleHsp" style=""></span>mg&#47;kg body weight&#44; administered intravenously every 4 weeks&#41; seems to be a safe and effective treatment in patients with active NMOSD and not responding to other immunosuppressants&#44; mainly RTX&#46; Further controlled studies with larger patient samples and longer follow-up periods are needed to assess the effectiveness of tocilizumab in NMOSD&#46;</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Conflicts of interest</span><p id="par0155" class="elsevierStylePara elsevierViewall">The authors have no conflicts of interest to declare&#46;</p></span></span>"
    "textoCompletoSecciones" => array:1 [
      "secciones" => array:11 [
        0 => array:3 [
          "identificador" => "xres1694983"
          "titulo" => "Abstract"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0005"
              "titulo" => "Introduction"
            ]
            1 => array:2 [
              "identificador" => "abst0010"
              "titulo" => "Method"
            ]
            2 => array:2 [
              "identificador" => "abst0015"
              "titulo" => "Results"
            ]
            3 => array:2 [
              "identificador" => "abst0020"
              "titulo" => "Conclusions"
            ]
          ]
        ]
        1 => array:2 [
          "identificador" => "xpalclavsec1501403"
          "titulo" => "Keywords"
        ]
        2 => array:3 [
          "identificador" => "xres1694984"
          "titulo" => "Resumen"
          "secciones" => array:4 [
            0 => array:2 [
              "identificador" => "abst0025"
              "titulo" => "Introducci&#243;n"
            ]
            1 => array:2 [
              "identificador" => "abst0030"
              "titulo" => "M&#233;todo"
            ]
            2 => array:2 [
              "identificador" => "abst0035"
              "titulo" => "Resultados"
            ]
            3 => array:2 [
              "identificador" => "abst0040"
              "titulo" => "Conclusiones"
            ]
          ]
        ]
        3 => array:2 [
          "identificador" => "xpalclavsec1501402"
          "titulo" => "Palabras clave"
        ]
        4 => array:2 [
          "identificador" => "sec0005"
          "titulo" => "Introduction"
        ]
        5 => array:2 [
          "identificador" => "sec0010"
          "titulo" => "Material and methods"
        ]
        6 => array:3 [
          "identificador" => "sec0015"
          "titulo" => "Results"
          "secciones" => array:2 [
            0 => array:2 [
              "identificador" => "sec0020"
              "titulo" => "Demographic and baseline clinical characteristics"
            ]
            1 => array:2 [
              "identificador" => "sec0025"
              "titulo" => "Effectiveness and safety of tocilizumab"
            ]
          ]
        ]
        7 => array:2 [
          "identificador" => "sec0030"
          "titulo" => "Discussion"
        ]
        8 => array:2 [
          "identificador" => "sec0035"
          "titulo" => "Conclusions"
        ]
        9 => array:2 [
          "identificador" => "sec0040"
          "titulo" => "Conflicts of interest"
        ]
        10 => array:1 [
          "titulo" => "References"
        ]
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "fechaRecibido" => "2018-07-02"
    "fechaAceptado" => "2018-12-22"
    "PalabrasClave" => array:2 [
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec1501403"
          "palabras" => array:4 [
            0 => "Neuromyelitis optica"
            1 => "Neuromyelitis optica spectrum disorders"
            2 => "Tocilizumab"
            3 => "Treatment"
          ]
        ]
      ]
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec1501402"
          "palabras" => array:4 [
            0 => "Neuromielitis &#243;ptica"
            1 => "Espectro de la neuromielitis &#243;ptica"
            2 => "Tocilizumab"
            3 => "Tratamiento"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "en" => array:3 [
        "titulo" => "Abstract"
        "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Introduction</span><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Neuromyelitis optica spectrum disorders &#40;NMOSD&#41; are immune-mediated inflammatory disorders of the central nervous system involving astrocytes&#44; B lymphocytes&#44; anti-aquaporin 4&#44; and such inflammatory mediators as interleukin-6&#46; Several immunosuppressants are used in their treatment&#46; Tocilizumab&#44; an interleukin-6 receptor antagonist&#44; may be a treatment option&#46;</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Method</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">We performed an observational&#44; retrospective study analysing parameters of effectiveness &#40;annualised relapse rate&#44; disability&#44; and radiological progression&#41; and safety of tocilizumab in patients with NMOSD in whom previous immunosuppressant treatment had failed&#46; We aimed to evaluate the effectiveness and safety of tocilizumab in clinical practice in patients with NMOSD not responding to other immunosuppressants&#46;</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">Five patients with NMOSD were analysed&#46; Sixty percent of patients were women&#59; mean age at diagnosis was 50<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>5&#46;3 years and mean progression time was 4&#46;5<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#46;6 years&#46; Previously administered immunosuppressants were rituximab &#40;in all 5&#41;&#44; cyclophosphamide &#40;2&#41;&#44; and azathioprine &#40;1&#41;&#46; Mean time of exposure to tocilizumab was 2&#46;3<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1 years&#46; Mean annualised relapse rate was 1&#46;8<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1&#46;3 in the year prior to the introduction of tocilizumab and 0&#46;2<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>0&#46;4 the year after &#40;<span class="elsevierStyleItalic">P</span><span class="elsevierStyleHsp" style=""></span>&#60;<span class="elsevierStyleHsp" style=""></span>&#46;05&#41;&#44; representing a reduction of 88&#46;9&#37;&#46;</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">In our experience&#44; tocilizumab is safe and effective in patients with NMOSD showing no response to other immunosuppressants&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0005"
            "titulo" => "Introduction"
          ]
          1 => array:2 [
            "identificador" => "abst0010"
            "titulo" => "Method"
          ]
          2 => array:2 [
            "identificador" => "abst0015"
            "titulo" => "Results"
          ]
          3 => array:2 [
            "identificador" => "abst0020"
            "titulo" => "Conclusions"
          ]
        ]
      ]
      "es" => array:3 [
        "titulo" => "Resumen"
        "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Introducci&#243;n</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">El espectro de la neuromielitis &#243;ptica &#40;ENMO&#41; es una enfermedad inflamatoria del sistema nervioso central con patogenia inmunomediada que implica a astrocitos&#44; linfocitos B&#44; anticuerpos antiacuaporina 4 y mediadores inflamatorios como la interleucina 6&#46; En su tratamiento se utilizan distintos inmunosupresores&#46; Tocilizumab&#44; un antagonista del receptor de interleucina 6&#44; podr&#237;a ser una opci&#243;n de tratamiento&#46;</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">M&#233;todo</span><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">Estudio observacional y retrospectivo en el que se analizan par&#225;metros de efectividad&#58; tasa anualizada de reca&#237;das&#44; discapacidad y evoluci&#243;n radiol&#243;gica&#44; y seguridad de tocilizumab en pacientes con ENMO &#40;Wingerchuk 2015&#41; y fracaso de inmunosupresores previos&#46; El objetivo es evaluar la efectividad y seguridad de tocilizumab en la pr&#225;ctica cl&#237;nica en pacientes con diagn&#243;stico de ENMO sin respuesta terap&#233;utica a otros inmunosupresores&#46;</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Se analizan 5 pacientes &#40;60&#37; mujeres&#41; con ENMO&#46; Caracter&#237;sticas basales &#40;media<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>DE&#41;&#58; edad al diagn&#243;stico 50<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>5&#44;3 a&#241;os&#59; tiempo de evoluci&#243;n desde el diagn&#243;stico 4&#44;5<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>3&#44;6 a&#241;os&#59; inmunosupresores previos rituximab &#40;5&#41;&#44; ciclofosfamida &#40;2&#41; y azatioprina &#40;1&#41;&#59; tiempo de exposici&#243;n a tocilizumab 2&#44;3<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1 a&#241;os&#59; tasa anual de reca&#237;das un a&#241;o pretocilizumab vs&#46; un a&#241;o postocilizumab 1&#44;8<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>1&#44;3 vs&#46; 0&#44;2<span class="elsevierStyleHsp" style=""></span>&#177;<span class="elsevierStyleHsp" style=""></span>0&#44;4 &#40;p &#60;<span class="elsevierStyleHsp" style=""></span>0&#44;05&#41;&#46; Reducci&#243;n de la tasa anual de reca&#237;das al a&#241;o de postocilizumab&#58; 88&#44;9&#37;&#46;</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusiones</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">En nuestra experiencia&#44; tocilizumab es seguro y efectivo en pacientes con ENMO sin respuesta a otros inmunosupresores&#46;</p></span>"
        "secciones" => array:4 [
          0 => array:2 [
            "identificador" => "abst0025"
            "titulo" => "Introducci&#243;n"
          ]
          1 => array:2 [
            "identificador" => "abst0030"
            "titulo" => "M&#233;todo"
          ]
          2 => array:2 [
            "identificador" => "abst0035"
            "titulo" => "Resultados"
          ]
          3 => array:2 [
            "identificador" => "abst0040"
            "titulo" => "Conclusiones"
          ]
        ]
      ]
    ]
    "NotaPie" => array:1 [
      0 => array:2 [
        "etiqueta" => "&#9734;"
        "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as&#58; Carre&#243;n Guarnizo E&#44; Hern&#225;ndez Clares R&#44; Castillo Trivi&#241;o T&#44; Meca Lallana V&#44; Arocas Casa&#241; V&#44; Iniesta Mart&#237;nez F&#44; et al&#46; Experiencia con tocilizumab en pacientes con espectro de la neuromielitis &#243;ptica&#46; Neurolog&#237;a&#46; 2022&#59;37&#58;178&#8211;183&#46;</p>"
      ]
    ]
    "multimedia" => array:1 [
      0 => array:8 [
        "identificador" => "tbl0005"
        "etiqueta" => "Table 1"
        "tipo" => "MULTIMEDIATABLA"
        "mostrarFloat" => true
        "mostrarDisplay" => false
        "detalles" => array:1 [
          0 => array:3 [
            "identificador" => "at0005"
            "detalle" => "Table "
            "rol" => "short"
          ]
        ]
        "tabla" => array:2 [
          "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">AQP4-IgG&#58; aquaporin-4 antibodies&#59; ARR&#58; annualised relapse rate&#59; AZA&#58; azathriopine&#59; CP&#58; cyclophosphamide&#59; DMT&#58; disease-modifying treatment&#59; EDSS&#58; Expanded Disability Status Scale&#59; Gd&#43;&#58; gadolinium-enhancing lesion&#59; Gd&#8722;&#58; lesion without gadolinium enhancement&#59; ITP&#58; immune thrombocytopaenia&#59; MRI&#58; magnetic resonance imaging&#59; RTX&#58; rituximab&#59; UTI&#58; urinary tract infection&#46;</p>"
          "tablatextoimagen" => array:1 [
            0 => array:2 [
              "tabla" => array:1 [
                0 => """
                  <table border="0" frame="\n
                  \t\t\t\t\tvoid\n
                  \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th><th class="td" title="\n
                  \t\t\t\t\ttable-head\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Patient 5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Baseline characteristics</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Sex&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Woman&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Woman&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Man&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Woman&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Man&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Age at onset &#40;years&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">39&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">34&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">50&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Age at diagnosis &#40;years&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">47&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">42&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">54&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">53&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>AQP4-IgG&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Positive&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Positive&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>MOG-IgG&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Negative&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Myelitis &#40;<span class="elsevierStyleItalic">n</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Optic neuritis &#40;<span class="elsevierStyleItalic">n</span>&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Previous DMT for NMO</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Years of progression until first treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&#46;2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">8&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>EDSS before first treatment&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Treatments &#40;years&#47;relapses&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">RTX &#40;2&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">RTX &#40;1&#46;5&#47;4&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">RTX &#40;0&#46;5&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">RTX &#40;0&#46;23&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">AZA &#40;3 months&#47;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CP &#40;1&#46;7&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CP &#40;0&#46;53&#47;2&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">RTX &#40;2 weeks&#47;1&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Last DMT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">RTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">RTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">CP&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">RTX&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Mean ARR in the last year&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Adverse events &#40;DMT&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">ITP &#40;RTX&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Haemorrhagic cystitis &#40;CP&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">UTI &#40;RTX&#44; CP&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Pancytopaenia &#40;AZA&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Serum sickness &#40;RTX&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>EDSS at end of the last DMT&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>MRI in the last year&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No new lesions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New spinal Gd&#8722; lesion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New spinal Gd&#43; lesion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New spinal GD&#8211; lesion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">New spinal GD&#43; lesion&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " colspan="6" align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleItalic">Treatment with tocilizumab</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Age at onset &#40;years&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">51&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">56&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">45&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">55&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">55&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Disease progression time at onset &#40;years&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">11&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">5&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Time taking tocilizumab &#40;years&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">2&#46;4&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Relapses after tocilizumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">0&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">1 &#40;third month&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>EDSS at 1 year&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>EDSS in the last follow-up visit&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">3&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">4&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&#46;5&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Adverse effects&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">Neutropaenia&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">UTI&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">None&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>MRI after tocilizumab &#40;months&#41;&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">7&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">12&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">6&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>MRI results after tocilizumab&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No new lesions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No new lesions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#62; 75&#37; reduction of the Gd&#43; area&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">No new lesions&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td><td class="td" title="\n
                  \t\t\t\t\ttable-entry\n
                  \t\t\t\t  " align="left" valign="\n
                  \t\t\t\t\ttop\n
                  \t\t\t\t">&#60; 75&#37; reduction of the Gd&#43; area&nbsp;\t\t\t\t\t\t\n
                  \t\t\t\t</td></tr></tbody></table>
                  """
              ]
              "imagenFichero" => array:1 [
                0 => "xTab2881474.png"
              ]
            ]
          ]
        ]
        "descripcion" => array:1 [
          "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Patients&#8217; baseline clinical characteristics and response to tocilizumab&#46;</p>"
        ]
      ]
    ]
    "bibliografia" => array:2 [
      "titulo" => "References"
      "seccion" => array:1 [
        0 => array:2 [
          "identificador" => "bibs0005"
          "bibliografiaReferencia" => array:25 [
            0 => array:3 [
              "identificador" => "bib0005"
              "etiqueta" => "1"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical characteristics&#44; course and prognosis of relapsing Devic&#39;s neuromyelitis optica"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Ghezzi"
                            1 => "R&#46; Bergamaschi"
                            2 => "V&#46; Martinelli"
                            3 => "M&#46; Trojano"
                            4 => "M&#46;R&#46; Tola"
                            5 => "E&#46; Merelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00415-004-0271-0"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Neurol"
                        "fecha" => "2004"
                        "volumen" => "251"
                        "paginaInicial" => "47"
                        "paginaFinal" => "52"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/14999489"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            1 => array:3 [
              "identificador" => "bib0010"
              "etiqueta" => "2"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of neuromyelitis optica with rituximab&#58; retrospective analysis of 25 patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Jacob"
                            1 => "B&#46;G&#46; Weinshenker"
                            2 => "I&#46; Violich"
                            3 => "N&#46; McLinskey"
                            4 => "L&#46; Krupp"
                            5 => "R&#46;J&#46; Fox"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/archneur.65.11.noc80069"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Neurol"
                        "fecha" => "2008"
                        "volumen" => "65"
                        "paginaInicial" => "1443"
                        "paginaFinal" => "1448"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18779415"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            2 => array:3 [
              "identificador" => "bib0015"
              "etiqueta" => "3"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;H&#46; Kim"
                            1 => "W&#46; Kim"
                            2 => "X&#46;F&#46; Li"
                            3 => "I&#46;J&#46; Jung"
                            4 => "H&#46;J&#46; Kim"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/archneurol.2011.154"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Neurol"
                        "fecha" => "2011"
                        "volumen" => "68"
                        "paginaInicial" => "1412"
                        "paginaFinal" => "1420"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21747007"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            3 => array:3 [
              "identificador" => "bib0020"
              "etiqueta" => "4"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "H&#46;L&#46; Pellkofer"
                            1 => "M&#46; Krumbholz"
                            2 => "A&#46; Berthele"
                            3 => "B&#46; Hemmer"
                            4 => "L&#46;A&#46; Gerdes"
                            5 => "J&#46; Havla"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1212/WNL.0b013e3182152881"
                      "Revista" => array:6 [
                        "tituloSerie" => "Neurology"
                        "fecha" => "2011"
                        "volumen" => "76"
                        "paginaInicial" => "1310"
                        "paginaFinal" => "1315"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21482945"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            4 => array:3 [
              "identificador" => "bib0025"
              "etiqueta" => "5"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of rituximab in refractory neuromyelitis optica"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "N&#46; Collongues"
                            1 => "D&#46; Brassat"
                            2 => "E&#46; Maillart"
                            3 => "P&#46; Labauge"
                            4 => "J&#46;C&#46; Ouallet"
                            5 => "C&#46; Carra-Dalliere"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1352458515602337"
                      "Revista" => array:6 [
                        "tituloSerie" => "Mult Scler"
                        "fecha" => "2016"
                        "volumen" => "22"
                        "paginaInicial" => "955"
                        "paginaFinal" => "959"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26362900"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            5 => array:3 [
              "identificador" => "bib0030"
              "etiqueta" => "6"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:5 [
                            0 => "S&#46;U&#46; Kim"
                            1 => "S&#46;Y&#46; Huh"
                            2 => "S&#46;J&#46; Lee"
                            3 => "A&#46; Joung"
                            4 => "H&#46;J&#46;A&#46; Kim"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamaneurol.2013.3071"
                      "Revista" => array:7 [
                        "tituloSerie" => "JAMA Neurol"
                        "fecha" => "2013"
                        "volumen" => "70"
                        "paginaInicial" => "1110"
                        "paginaFinal" => "11175"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23897062"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0015028217304314"
                          "estado" => "S300"
                          "issn" => "00150282"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            6 => array:3 [
              "identificador" => "bib0035"
              "etiqueta" => "7"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Neuromyelitis optica spectrum disorders&#58; long-term safety and efficacy of rituximab in Caucasian patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Radaelli"
                            1 => "L&#46; Moiola"
                            2 => "F&#46; Sangalli"
                            3 => "F&#46; Esposito"
                            4 => "V&#46; Barcella"
                            5 => "L&#46; Ferr&#232;"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1352458515594042"
                      "Revista" => array:6 [
                        "tituloSerie" => "Mult Scler"
                        "fecha" => "2016"
                        "volumen" => "22"
                        "paginaInicial" => "511"
                        "paginaFinal" => "519"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26199350"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            7 => array:3 [
              "identificador" => "bib0040"
              "etiqueta" => "8"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Rituximab in the treatment of neuromyelitis optica&#58; a multicentre Italian observational study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "P&#46; Annovazzi"
                            1 => "M&#46; Capobianco"
                            2 => "L&#46; Moiola"
                            3 => "F&#46; Patti"
                            4 => "J&#46; Frau"
                            5 => "A&#46; Uccelli"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00415-016-8188-y"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Neurol"
                        "fecha" => "2016"
                        "volumen" => "263"
                        "paginaInicial" => "1727"
                        "paginaFinal" => "1735"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27286847"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            8 => array:3 [
              "identificador" => "bib0045"
              "etiqueta" => "9"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders&#46; A systematic review and meta-analysis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:3 [
                            0 => "V&#46; Damato"
                            1 => "A&#46; Evoli"
                            2 => "R&#46; Iorio"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamaneurol.2016.1637"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Neurol"
                        "fecha" => "2016"
                        "volumen" => "73"
                        "paginaInicial" => "1342"
                        "paginaFinal" => "1348"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27668357"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            9 => array:3 [
              "identificador" => "bib0050"
              "etiqueta" => "10"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Markedly increased CSF interlecukin-6 levels in NMO&#44; but not in multiple sclerosis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Uzawa"
                            1 => "M&#46; Mori"
                            2 => "M&#46; Ito"
                            3 => "T&#46; Uchida"
                            4 => "S&#46; Hayakawa"
                            5 => "S&#46; Masuda"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s00415-009-5274-4"
                      "Revista" => array:6 [
                        "tituloSerie" => "J Neurol"
                        "fecha" => "2009"
                        "volumen" => "256"
                        "paginaInicial" => "2082"
                        "paginaFinal" => "2084"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19655191"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            10 => array:3 [
              "identificador" => "bib0055"
              "etiqueta" => "11"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Cytokine and chemokine profiles in neuromyelitis optica&#58; significance of interleukin-6"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "A&#46; Uzawa"
                            1 => "M&#46; Mori"
                            2 => "K&#46; Arai"
                            3 => "Y&#46; Sato"
                            4 => "S&#46; Hayakawa"
                            5 => "S&#46; Masuda"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1352458510379247"
                      "Revista" => array:7 [
                        "tituloSerie" => "Mult Scler"
                        "fecha" => "2010"
                        "volumen" => "16"
                        "paginaInicial" => "1443"
                        "paginaFinal" => "1452"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20739337"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0010782408003776"
                          "estado" => "S300"
                          "issn" => "00107824"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            11 => array:3 [
              "identificador" => "bib0060"
              "etiqueta" => "12"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interleukin 6 signaling promotes antiaquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "N&#46; Chihara"
                            1 => "T&#46; Aranami"
                            2 => "W&#46; Sato"
                            3 => "Y&#46; Miyazaki"
                            4 => "S&#46; Miyake"
                            5 => "T&#46; Okamoto"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1073/pnas.1017385108"
                      "Revista" => array:6 [
                        "tituloSerie" => "Proc Natl Acad Sci U S A"
                        "fecha" => "2011"
                        "volumen" => "108"
                        "paginaInicial" => "3701"
                        "paginaFinal" => "3706"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21321193"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            12 => array:3 [
              "identificador" => "bib0065"
              "etiqueta" => "13"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#231;&#246;z S1"
                            1 => "E&#46; T&#252;z&#252;n"
                            2 => "M&#46; K&#252;rt&#252;nc&#252;"
                            3 => "H&#46; Durmu&#351;"
                            4 => "M&#46; Mutlu"
                            5 => "M&#46; Eraksoy"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.3109/00207450903428970"
                      "Revista" => array:6 [
                        "tituloSerie" => "Int J Neurosci"
                        "fecha" => "2010"
                        "volumen" => "120"
                        "paginaInicial" => "71"
                        "paginaFinal" => "75"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/20128675"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            13 => array:3 [
              "identificador" => "bib0070"
              "etiqueta" => "14"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromielitis optica&#58; a pilot study"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46; Araki"
                            1 => "T&#46; Matsuoka"
                            2 => "K&#46; Miyamoto"
                            3 => "S&#46; Kusunoki"
                            4 => "T&#46; Okamoto"
                            5 => "M&#46; Murata"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1212/WNL.0000000000000317"
                      "Revista" => array:7 [
                        "tituloSerie" => "Neurology"
                        "fecha" => "2014"
                        "volumen" => "82"
                        "paginaInicial" => "1302"
                        "paginaFinal" => "1306"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24634453"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S001078241730478X"
                          "estado" => "S300"
                          "issn" => "00107824"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            14 => array:3 [
              "identificador" => "bib0075"
              "etiqueta" => "15"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Tocilizumab&#58; a review of its safety and efficacy in rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:2 [
                            0 => "G&#46; Jones"
                            1 => "C&#46; Ding"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4137/CMAMD.S4864"
                      "Revista" => array:6 [
                        "tituloSerie" => "Clin Med Insights Arthritis Musculoskelet Disord"
                        "fecha" => "2010"
                        "volumen" => "3"
                        "paginaInicial" => "81"
                        "paginaFinal" => "89"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21234291"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            15 => array:3 [
              "identificador" => "bib0080"
              "etiqueta" => "16"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica implication for cellular immune responses"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "B&#46;C&#46; Kieseier"
                            1 => "O&#46; St&#252;ve"
                            2 => "T&#46; Dehmel"
                            3 => "N&#46; Goebels"
                            4 => "V&#46;I&#46; Leussink"
                            5 => "A&#46;K&#46; Mausberg"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamaneurol.2013.668"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Neurol"
                        "fecha" => "2013"
                        "volumen" => "70"
                        "paginaInicial" => "390"
                        "paginaFinal" => "393"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23599943"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            16 => array:3 [
              "identificador" => "bib0085"
              "etiqueta" => "17"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "International consensus diagnostic criteria for neuromyelitis optica spectrum disorders"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "D&#46;M&#46; Wingerchuk"
                            1 => "B&#46; Banwell"
                            2 => "J&#46;L&#46; Bennett"
                            3 => "P&#46; Cabre"
                            4 => "W&#46; Carroll"
                            5 => "T&#46; Chitnis"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1212/WNL.0000000000001729"
                      "Revista" => array:7 [
                        "tituloSerie" => "Neurology"
                        "fecha" => "2015"
                        "volumen" => "85"
                        "paginaInicial" => "177"
                        "paginaFinal" => "189"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26092914"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0010782415301396"
                          "estado" => "S300"
                          "issn" => "00107824"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            17 => array:3 [
              "identificador" => "bib0090"
              "etiqueta" => "18"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:6 [
                            0 => "M&#46; Araki"
                            1 => "T&#46; Aranami"
                            2 => "T&#46; Matsuoka"
                            3 => "M&#46; Nakamura"
                            4 => "S&#46; Miyake"
                            5 => "T&#46; Yamamura"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1007/s10165-012-0715-9"
                      "Revista" => array:6 [
                        "tituloSerie" => "Mod Rheumatol"
                        "fecha" => "2013"
                        "volumen" => "23"
                        "paginaInicial" => "827"
                        "paginaFinal" => "831"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22782533"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            18 => array:3 [
              "identificador" => "bib0095"
              "etiqueta" => "19"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46; Ayzenberg"
                            1 => "I&#46; Kleiter"
                            2 => "A&#46; Schroder"
                            3 => "K&#46; Hellwig"
                            4 => "A&#46; Chan"
                            5 => "T&#46; Yamamura"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamaneurol.2013.1246"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Neurol"
                        "fecha" => "2013"
                        "volumen" => "70"
                        "paginaInicial" => "394"
                        "paginaFinal" => "397"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23358868"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            19 => array:3 [
              "identificador" => "bib0100"
              "etiqueta" => "20"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treating neuromyelitis optica with the interleukin-6 receptor antagonist tocilizumab"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46;S&#46; Lauenstein"
                            1 => "M&#46; Stettner"
                            2 => "B&#46;C&#46; Kieseier"
                            3 => "E&#46; Lensch"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:1 [
                      "Revista" => array:4 [
                        "tituloSerie" => "Case Rep"
                        "fecha" => "2014"
                        "volumen" => "26"
                        "paginaInicial" => "2014"
                      ]
                    ]
                  ]
                ]
              ]
            ]
            20 => array:3 [
              "identificador" => "bib0105"
              "etiqueta" => "21"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "M&#46; Ringelstein"
                            1 => "I&#46; Ayzenberg"
                            2 => "J&#46; Harmel"
                            3 => "A&#46;S&#46; Lauenstein"
                            4 => "E&#46; Lensch"
                            5 => "F&#46; Stogbauer"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/jamaneurol.2015.0533"
                      "Revista" => array:6 [
                        "tituloSerie" => "JAMA Neurol"
                        "fecha" => "2015"
                        "volumen" => "72"
                        "paginaInicial" => "756"
                        "paginaFinal" => "776"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25985228"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            21 => array:3 [
              "identificador" => "bib0110"
              "etiqueta" => "22"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Treatment of neuromyelitis optica&#58; current debate"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => true
                          "autores" => array:6 [
                            0 => "T&#46; Okamoto"
                            1 => "M&#46; Ogawa"
                            2 => "Y&#46; Lin"
                            3 => "M&#46; Murata"
                            4 => "S&#46; Miyake"
                            5 => "T&#46; Yamamura"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1177/1756285608093978"
                      "Revista" => array:6 [
                        "tituloSerie" => "Ther Adv Neurol Disord"
                        "fecha" => "2008"
                        "volumen" => "1"
                        "paginaInicial" => "5"
                        "paginaFinal" => "12"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21180560"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            22 => array:3 [
              "identificador" => "bib0115"
              "etiqueta" => "23"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Failure of natalizumab to prevent relapses in neuromyelitis optica"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "Neuromyelitis Optica Study Group"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "I&#46; Kleiter"
                            1 => "K&#46; Hellwig"
                            2 => "A&#46; Berthele"
                            3 => "T&#46; K&#252;mpfel"
                            4 => "R&#46;A&#46; Linker"
                            5 => "H&#46;P&#46; Hartung"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1001/archneurol.2011.216"
                      "Revista" => array:6 [
                        "tituloSerie" => "Arch Neurol"
                        "fecha" => "2012"
                        "volumen" => "69"
                        "paginaInicial" => "239"
                        "paginaFinal" => "245"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22332191"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            23 => array:3 [
              "identificador" => "bib0120"
              "etiqueta" => "24"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis &#40;OPTION study&#41;&#58; a double-blind&#44; placebo-controlled&#44; randomised trial"
                      "autores" => array:1 [
                        0 => array:3 [
                          "colaboracion" => "OPTION Investigators"
                          "etal" => true
                          "autores" => array:6 [
                            0 => "J&#46;S&#46; Smolen"
                            1 => "A&#46; Beaulieu"
                            2 => "A&#46; Rubbert-Roth"
                            3 => "C&#46; Ramos-Remus"
                            4 => "J&#46; Rovensky"
                            5 => "E&#46; Alecock"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.1016/S0140-6736(08)60453-5"
                      "Revista" => array:6 [
                        "tituloSerie" => "Lancet"
                        "fecha" => "2008"
                        "volumen" => "371"
                        "paginaInicial" => "987"
                        "paginaFinal" => "997"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18358926"
                            "web" => "Medline"
                          ]
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
            24 => array:3 [
              "identificador" => "bib0125"
              "etiqueta" => "25"
              "referencia" => array:1 [
                0 => array:2 [
                  "contribucion" => array:1 [
                    0 => array:2 [
                      "titulo" => "Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis"
                      "autores" => array:1 [
                        0 => array:2 [
                          "etal" => false
                          "autores" => array:4 [
                            0 => "A&#46; Ogata"
                            1 => "T&#46; Hirano"
                            2 => "Y&#46; Hishitani"
                            3 => "T&#46; Tanaka"
                          ]
                        ]
                      ]
                    ]
                  ]
                  "host" => array:1 [
                    0 => array:2 [
                      "doi" => "10.4137/CMAMD.S7371"
                      "Revista" => array:7 [
                        "tituloSerie" => "Clin Med Insights Arthritis Musculoskelet Disord"
                        "fecha" => "2012"
                        "volumen" => "5"
                        "paginaInicial" => "27"
                        "paginaFinal" => "42"
                        "link" => array:1 [
                          0 => array:2 [
                            "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22438671"
                            "web" => "Medline"
                          ]
                        ]
                        "itemHostRev" => array:3 [
                          "pii" => "S0010782414000353"
                          "estado" => "S300"
                          "issn" => "00107824"
                        ]
                      ]
                    ]
                  ]
                ]
              ]
            ]
          ]
        ]
      ]
    ]
  ]
  "idiomaDefecto" => "en"
  "url" => "/21735808/0000003700000003/v1_202204220526/S2173580821000237/v1_202204220526/en/main.assets"
  "Apartado" => array:4 [
    "identificador" => "9491"
    "tipo" => "SECCION"
    "en" => array:2 [
      "titulo" => "Original Articles"
      "idiomaDefecto" => true
    ]
    "idiomaDefecto" => "en"
  ]
  "PDF" => "https://static.elsevier.es/multimedia/21735808/0000003700000003/v1_202204220526/S2173580821000237/v1_202204220526/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2173580821000237?idApp=UINPBA00004N"
]

Article information

ISSN: 21735808
Original language: English

DOI:10.1016/j.nrleng.2018.12.021

The statistics are updated each day

Year/Month	Html	Pdf	Total

2024 November	4	0	4
2024 October	31	10	41
2024 September	33	5	38
2024 August	23	6	29
2024 July	34	6	40
2024 June	28	9	37
2024 May	22	12	34
2024 April	26	10	36
2024 March	67	13	80
2024 February	61	5	66
2024 January	44	15	59
2023 December	44	11	55
2023 November	57	16	73
2023 October	58	11	69
2023 September	44	6	50
2023 August	40	6	46
2023 July	56	12	68
2023 June	44	10	54
2023 May	73	11	84
2023 April	45	10	55
2023 March	45	10	55
2023 February	43	26	69
2023 January	31	14	45
2022 December	50	9	59
2022 November	61	19	80
2022 October	36	9	45
2022 September	41	9	50
2022 August	38	11	49
2022 July	26	11	37
2022 June	22	5	27
2022 May	31	15	46
2022 April	11	11	22
2022 March	15	7	22
2022 February	10	10	20
2022 January	11	7	18
2021 December	12	15	27
2021 November	12	11	23
2021 October	19	11	30
2021 September	10	9	19
2021 August	12	6	18
2021 July	6	8	14
2021 June	13	7	20
2021 May	10	8	18
2021 April	11	3	14
2021 March	20	9	29
2021 February	2	0	2

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter